CD30	B-protein
-dependent	O
degradation	O
of	O
TRAF2	B-protein
:	O
implications	O
for	O
negative	O
regulation	O
of	O
TRAF	B-protein
signaling	O
and	O
the	O
control	O
of	O
cell	O
survival	O
.	O

CD30	B-protein
is	O
a	O
cell-surface	B-protein
receptor	I-protein
that	O
can	O
augment	O
lymphocyte	O
activation	O
and	O
survival	O
through	O
its	O
ability	O
to	O
induce	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
.	O

CD30	B-protein
,	O
however	O
,	O
has	O
also	O
been	O
implicated	O
in	O
the	O
induction	O
of	O
apoptotic	O
cell	O
death	O
of	O
lymphocytes	B-cell_type
.	O

Here	O
we	O
show	O
that	O
one	O
of	O
the	O
effects	O
of	O
CD30	B-protein
signal	O
transduction	O
is	O
to	O
render	O
cells	O
sensitive	O
to	O
apoptosis	O
induced	O
by	O
the	O
type	B-protein
1	I-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
(	O
TNFR1	B-protein
)	O
.	O

This	O
sensitization	O
is	O
dependent	O
on	O
the	O
TRAF-binding	B-protein
sites	I-protein
within	O
the	O
CD30	B-protein
cytoplasmic	B-protein
domain	I-protein
.	O

One	O
of	O
the	O
proteins	O
that	O
binds	O
to	O
these	O
sites	O
is	O
TRAF2	B-protein
,	O
a	O
signal	B-protein
transduction	I-protein
molecule	I-protein
that	O
is	O
also	O
utilized	O
by	O
TNFR1	B-protein
to	O
mediate	O
the	O
activation	O
of	O
several	O
downstream	O
kinases	B-protein
and	O
transcription	B-protein
factors	I-protein
.	O

During	O
CD30	B-protein
signal	O
transduction	O
,	O
we	O
found	O
that	O
binding	O
of	O
TRAF2	B-protein
to	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
CD30	B-protein
results	O
in	O
the	O
rapid	O
depletion	O
of	O
TRAF2	B-protein
and	O
the	O
associated	O
protein	O
TRAF1	B-protein
by	O
proteolysis	O
.	O

These	O
data	O
suggest	O
a	O
model	O
in	O
which	O
CD30	B-protein
limits	O
its	O
own	O
ability	O
to	O
transduce	O
cell	O
survival	O
signals	O
through	O
signal-coupled	O
depletion	O
of	O
TRAF2	B-protein
.	O

Depletion	O
of	O
intracellular	O
TRAF2	B-protein
and	O
its	O
coassociated	B-protein
proteins	I-protein
also	O
increased	O
the	O
sensitivity	O
of	O
the	O
cell	O
to	O
undergoing	O
apoptosis	O
during	O
activation	O
of	O
death-inducing	B-protein
receptors	I-protein
such	O
as	O
TNFR1	B-protein
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
expression	O
of	O
a	O
dominant-negative	B-protein
form	I-protein
of	O
TRAF2	B-protein
was	O
found	O
to	O
potentiate	O
TNFR1	B-protein
-mediated	O
death	O
.	O

These	O
studies	O
provide	O
a	O
potential	O
mechanism	O
through	O
which	O
CD30	B-protein
,	O
as	O
well	O
as	O
other	O
TRAF-binding	B-protein
members	I-protein
of	O
the	O
TNFR	B-protein
superfamily	I-protein
,	O
can	O
negatively	O
regulate	O
cell	O
survival	O
.	O

CD30-dependent	NULL
degradation	NULL
of	NULL
TRAF2	NULL
:	NULL
im	NULL
plications	NULL
for	NULL
negative	NULL
regulation	NULL
of	NULL
TRAF	NULL
signaling	NULL
and	NULL
the	NULL
control	NULL
of	NULL
cell	NULL
survival	NULL
Colin	NULL
S.	NULL
Duckett	NULL
'	NULL
and	NULL
Craig	NULL
B.	NULL
Thompson	NULL
``	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
,	NULL
Gwen	NULL
Knapp	NULL
Center	NULL
for	NULL
Lupus	NULL
and	NULL
Immunology	NULL
Research	NULL
,	NULL
and	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
The	NULL
University	NULL
of	NULL
Chicago	NULL
,	NULL
Chicago	NULL
,	NULL
Illinois	NULL
60637	NULL
USA	NULL
CD30	NULL
is	NULL
a	NULL
cell-surface	NULL
receptor	NULL
that	NULL
can	NULL
augment	NULL
lymphocyte	NULL
activation	NULL
and	NULL
survival	NULL
through	NULL
its	NULL
ability	NULL
to	NULL
induce	NULL
the	NULL
transcription	NULL
factor	NULL
NF-KB	NULL
.	NULL

CD30	NULL
,	NULL
however	NULL
,	NULL
has	NULL
also	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
apoptotic	NULL
cell	NULL
death	NULL
of	NULL
lymphocytes	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
one	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
CD30	NULL
signal	NULL
transduction	NULL
is	NULL
to	NULL
render	NULL
cells	NULL
sensitive	NULL
to	NULL
apoptosis	NULL
induced	NULL
by	NULL
the	NULL
type	NULL
1	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
(	NULL
INFR1	NULL
)	NULL
.	NULL

This	NULL
sensitization	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
TRAF-binding	NULL
sites	NULL
within	NULL
the	NULL
CD30	NULL
cytoplasmic	NULL
domain	NULL
.	NULL

One	NULL
of	NULL
the	NULL
proteins	NULL
that	NULL
binds	NULL
to	NULL
these	NULL
sites	NULL
is	NULL
TRAF2	NULL
,	NULL
a	NULL
signal	NULL
transduction	NULL
molecule	NULL
that	NULL
is	NULL
also	NULL
utilized	NULL
by	NULL
TNFR1	NULL
to	NULL
mediate	NULL
the	NULL
activation	NULL
of	NULL
several	NULL
downstream	NULL
kinases	NULL
and	NULL
transcription	NULL
factors	NULL
.	NULL

During	NULL
CD30	NULL
signal	NULL
transduction	NULL
,	NULL
we	NULL
found	NULL
that	NULL
binding	NULL
of	NULL
TRAF2	NULL
to	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
CD30	NULL
results	NULL
in	NULL
the	NULL
rapid	NULL
depletion	NULL
of	NULL
TRAF	NULL
and	NULL
the	NULL
associated	NULL
protein	NULL
TRAF1	NULL
by	NULL
proteolysis	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
a	NULL
model	NULL
in	NULL
which	NULL
CD30	NULL
limits	NULL
its	NULL
own	NULL
ability	NULL
to	NULL
transduce	NULL
cell	NULL
survival	NULL
signals	NULL
through	NULL
signal-coupled	NULL
depletion	NULL
of	NULL
TRAF2	NULL
.	NULL

Depletion	NULL
of	NULL
intracellular	NULL
TRAF	NULL
and	NULL
its	NULL
coassociated	NULL
proteins	NULL
also	NULL
increased	NULL
the	NULL
sensitivity	NULL
of	NULL
the	NULL
cell	NULL
to	NULL
undergoing	NULL
apoptosis	NULL
during	NULL
activation	NULL
of	NULL
death-inducing	NULL
receptors	NULL
such	NULL
as	NULL
TNFR1	NULL
.	NULL

Consistent	NULL
with	NULL
this	NULL
hypothesis	NULL
,	NULL
expression	NULL
of	NULL
a	NULL
dominant-negative	NULL
form	NULL
of	NULL
TRAF	NULL
was	NULL
found	NULL
to	NULL
potentiate	NULL
TNFR1-mediated	NULL
death	NULL
.	NULL

These	NULL
studies	NULL
provide	NULL
a	NULL
potential	NULL
mechanism	NULL
through	NULL
which	NULL
CD30	NULL
,	NULL
as	NULL
well	NULL
as	NULL
other	NULL
TRAF-binding	NULL
members	NULL
of	NULL
the	NULL
TNFR	NULL
superfamily	NULL
,	NULL
can	NULL
negatively	NULL
regulate	NULL
cell	NULL
survival	NULL
.	NULL

[	NULL
Key	NULL
Words	NULL
:	NULL
Apoptosis	NULL
;	NULL
NF-kB	NULL
;	NULL
CD30	NULL
;	NULL
TRAF	NULL
;	NULL
TNF	NULL
;	NULL
proteases	NULL
]	NULL
Received	NULL
July	NULL
7	NULL
,	NULL
1997	NULL
;	NULL
revised	NULL
version	NULL
accepted	NULL
August	NULL
27	NULL
,	NULL
1997	NULL
.	NULL

An	NULL
essential	NULL
feature	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
is	NULL
the	NULL
ability	NULL
to	NULL
tolerate	NULL
large	NULL
fluctuations	NULL
in	NULL
cell	NULL
number	NULL
.	NULL

Homeosta-sis	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
achieved	NULL
through	NULL
the	NULL
integration	NULL
of	NULL
intracellular	NULL
and	NULL
extracellular	NULL
signals	NULL
that	NULL
function	NULL
to	NULL
balance	NULL
the	NULL
degree	NULL
of	NULL
cell	NULL
proliferation	NULL
with	NULL
the	NULL
rate	NULL
of	NULL
cell	NULL
death	NULL
(	NULL
Oltvai	NULL
and	NULL
Korsmeyer	NULL
1994	NULL
;	NULL
Allison	NULL
and	NULL
Krummel	NULL
1995	NULL
)	NULL
.	NULL

Lymphocyte	NULL
activation	NULL
and	NULL
proliferation	NULL
is	NULL
initiated	NULL
by	NULL
the	NULL
engagement	NULL
of	NULL
antigen	NULL
with	NULL
its	NULL
clonotypic	NULL
cell-surface	NULL
receptor	NULL
(	NULL
Weiss	NULL
and	NULL
Littman	NULL
1994	NULL
)	NULL
.	NULL

Additional	NULL
costimulatory	NULL
signals	NULL
,	NULL
however	NULL
,	NULL
are	NULL
also	NULL
required	NULL
.	NULL

For	NULL
example	NULL
,	NULL
costimulatory	NULL
signals	NULL
can	NULL
be	NULL
mediated	NULL
in	NULL
T	NULL
cells	NULL
by	NULL
signaling	NULL
through	NULL
the	NULL
CD28	NULL
receptor	NULL
(	NULL
Allison	NULL
and	NULL
Krummel	NULL
1995	NULL
)	NULL
and	NULL
in	NULL
B	NULL
cells	NULL
through	NULL
the	NULL
CD40	NULL
receptor	NULL
,	NULL
a	NULL
member	NULL
of	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor/nerve	NULL
growth	NULL
factor	NULL
(	NULL
INF/NGF	NULL
)	NULL
receptor	NULL
superfamily	NULL
(	NULL
Choi	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
.	NULL

The	NULL
TNF/NGF	NULL
receptor	NULL
superfamily	NULL
is	NULL
a	NULL
group	NULL
of	NULL
re	NULL
'Present	NULL
address	NULL
:	NULL
Metabolism	NULL
Branch	NULL
,	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
20892	NULL
.	NULL

*Corresponding	NULL
author	NULL
.	NULL

E-MAIL	NULL
Craig	NULL
@	NULL
Knapp.uchicago.edu	NULL
;	NULL
FAX	NULL
(	NULL
773	NULL
)	NULL
702-1576.	NULL
lated	NULL
cell-surface	NULL
receptors	NULL
that	NULL
include	NULL
the	NULL
types	NULL
1	NULL
and	NULL
2	NULL
TNF	NULL
receptors	NULL
(	NULL
INFR1	NULL
and	NULL
TNFR2	NULL
)	NULL
,	NULL
Fas	NULL
,	NULL
CD27	NULL
,	NULL
4-1BB	NULL
,	NULL
and	NULL
CD30	NULL
(	NULL
Vassalli	NULL
1992	NULL
;	NULL
Armitage	NULL
1994	NULL
;	NULL
Beyaert	NULL
and	NULL
Fiers	NULL
1994	NULL
;	NULL
Gruss	NULL
and	NULL
Dower	NULL
1995	NULL
)	NULL
.	NULL

Many	NULL
of	NULL
these	NULL
receptors	NULL
have	NULL
been	NULL
found	NULL
to	NULL
play	NULL
costimulatory	NULL
roles	NULL
in	NULL
cell	NULL
proliferation	NULL
,	NULL
whereas	NULL
others	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
apoptosis	NULL
.	NULL

Interestingly	NULL
,	NULL
several	NULL
members	NULL
of	NULL
this	NULL
family	NULL
,	NULL
such	NULL
as	NULL
TNFR2	NULL
(	NULL
Tartaglia	NULL
et	NULL
al	NULL
.	NULL

1993	NULL
;	NULL
Zheng	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
,	NULL
CD40	NULL
(	NULL
Foy	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Rathmell	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
,	NULL
and	NULL
CD30	NULL
(	NULL
see	NULL
below	NULL
)	NULL
,	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
play	NULL
dual	NULL
roles	NULL
,	NULL
although	NULL
the	NULL
mechanism	NULL
(	NULL
s	NULL
)	NULL
underlying	NULL
this	NULL
apparent	NULL
am	NULL
biguity	NULL
is	NULL
unknown	NULL
.	NULL

To	NULL
understand	NULL
this	NULL
phenomenon	NULL
,	NULL
we	NULL
have	NULL
examined	NULL
the	NULL
signaling	NULL
properties	NULL
of	NULL
one	NULL
of	NULL
these	NULL
receptors	NULL
,	NULL
CD30	NULL
.	NULL

CD30	NULL
is	NULL
a	NULL
lymphoid	NULL
cell-restricted	NULL
receptor	NULL
(	NULL
Diirkop	NULL
et	NULL
al	NULL
.	NULL

1992	NULL
)	NULL
that	NULL
is	NULL
normally	NULL
expressed	NULL
on	NULL
activated	NULL
and	NULL
memory	NULL
T	NULL
cells	NULL
(	NULL
Ellis	NULL
et	NULL
al	NULL
.	NULL

1993	NULL
)	NULL
.	NULL

CD30	NULL
was	NULL
originally	NULL
identified	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
Hodgkin	NULL
's	NULL
lymphoma	NULL
cells	NULL
(	NULL
Schwab	NULL
et	NULL
al	NULL
.	NULL

1982	NULL
;	NULL
Stein	NULL
et	NULL
al	NULL
.	NULL

1985b	NULL
;	NULL
Falini	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
,	NULL
and	NULL
high	NULL
levels	NULL
of	NULL
CD30	NULL
expression	NULL
have	NULL
also	NULL
been	NULL
found	NULL
to	NULL
correlate	NULL
with	NULL
disease	NULL
progression	NULL
in	NULL
anaplastic	NULL
large	NULL
cell	NULL
lymphoma	NULL
(	NULL
Nadali	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
.	NULL

Signal	NULL
transduction	NULL
2810	NULL
GENES	NULL
&	NULL
DEVELOPMENT	NULL
11:2810-2821	NULL
©	NULL
1997	NULL
by	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
Press	NULL
ISSN	NULL
0890-9369/97	NULL
$	NULL
5.00	NULL
through	NULL
CD30	NULL
has	NULL
been	NULL
found	NULL
to	NULL
augment	NULL
T-cell	NULL
receptor-mediated	NULL
proliferation	NULL
under	NULL
some	NULL
circumstances	NULL
(	NULL
Smith	NULL
et	NULL
al	NULL
.	NULL

1993	NULL
)	NULL
,	NULL
but	NULL
in	NULL
other	NULL
cases	NULL
to	NULL
potentiate	NULL
apoptosis	NULL
(	NULL
Lee	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
CD30	NULL
has	NULL
also	NULL
been	NULL
shown	NULL
to	NULL
stimulate	NULL
HIV	NULL
expression	NULL
(	NULL
Maggi	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
,	NULL
probably	NULL
through	NULL
its	NULL
ability	NULL
to	NULL
activate	NULL
the	NULL
transcription	NULL
factor	NULL
NF-kB	NULL
(	NULL
Siebenlist	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
;	NULL
Biswas	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
.	NULL

Targeted	NULL
disruption	NULL
of	NULL
the	NULL
murine	NULL
CD30	NULL
gene	NULL
,	NULL
however	NULL
,	NULL
has	NULL
implicated	NULL
CD30	NULL
in	NULL
thymic	NULL
negative	NULL
selection	NULL
(	NULL
Amakawa	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

The	NULL
signaling	NULL
properties	NULL
of	NULL
TNFR-related	NULL
receptors	NULL
are	NULL
being	NULL
rapidly	NULL
elucidated	NULL
.	NULL

Several	NULL
TNF	NULL
receptor	NULL
family	NULL
members	NULL
,	NULL
including	NULL
Fas	NULL
,	NULL
TNFR1	NULL
,	NULL
and	NULL
DR3/Wsl/	NULL
Apo-3	NULL
,	NULL
have	NULL
been	NULL
found	NULL
to	NULL
contain	NULL
an	NULL
~80-residue	NULL
motif	NULL
designated	NULL
the	NULL
death	NULL
domain	NULL
(	NULL
Tartaglia	NULL
et	NULL
al	NULL
.	NULL

1993	NULL
;	NULL
Takahashi	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
;	NULL
Chinnaiyan	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Kitson	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Marsters	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Pan	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
,	NULL
and	NULL
signaling	NULL
through	NULL
these	NULL
receptors	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
apoptosis	NULL
in	NULL
a	NULL
manner	NULL
that	NULL
is	NULL
dependent	NULL
on	NULL
dimerization	NULL
of	NULL
the	NULL
death	NULL
domain	NULL
of	NULL
the	NULL
receptor	NULL
with	NULL
similar	NULL
death	NULL
domains	NULL
of	NULL
cytoplasmic	NULL
factors	NULL
such	NULL
as	NULL
FADD	NULL
,	NULL
TRADD	NULL
,	NULL
and	NULL
RIP	NULL
(	NULL
Chinnaiyan	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
;	NULL
Hsu	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
;	NULL
Stanger	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
cytoplasmic	NULL
domains	NULL
of	NULL
a	NULL
num	NULL
ber	NULL
of	NULL
other	NULL
TNF	NULL
receptor	NULL
family	NULL
members	NULL
,	NULL
including	NULL
TNFR2	NULL
and	NULL
CD40	NULL
,	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
interact	NULL
with	NULL
members	NULL
of	NULL
the	NULL
recently	NULL
described	NULL
TNF	NULL
receptor-associated	NULL
factor	NULL
(	NULL
TRAF	NULL
)	NULL
family	NULL
of	NULL
signaling	NULL
molecules	NULL
(	NULL
Baker	NULL
and	NULL
Reddy	NULL
1996	NULL
)	NULL
.	NULL

We	NULL
and	NULL
others	NULL
have	NULL
recently	NULL
identified	NULL
TRAF1	NULL
,	NULL
TRAF2	NULL
,	NULL
TRAF3	NULL
,	NULL
and	NULL
TRAFS	NULL
as	NULL
factors	NULL
that	NULL
can	NULL
be	NULL
recruited	NULL
to	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
CD30	NULL
and	NULL
have	NULL
shown	NULL
that	NULL
these	NULL
molecules	NULL
play	NULL
central	NULL
roles	NULL
in	NULL
signal	NULL
transduction	NULL
through	NULL
this	NULL
receptor	NULL
(	NULL
Ansieau	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Gedrich	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Lee	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Aizawa	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
;	NULL
Duckett	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
;	NULL
Tsitsikov	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

Six	NULL
mammalian	NULL
TRAF	NULL
proteins	NULL
have	NULL
been	NULL
identified	NULL
to	NULL
date	NULL
(	NULL
Baker	NULL
and	NULL
Reddy	NULL
1996	NULL
)	NULL
.	NULL

These	NULL
factors	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
possess	NULL
distinct	NULL
affinities	NULL
for	NULL
different	NULL
members	NULL
of	NULL
the	NULL
TNF	NULL
receptor	NULL
superfamily	NULL
.	NULL

The	NULL
TRAF	NULL
proteins	NULL
have	NULL
been	NULL
suggested	NULL
to	NULL
be	NULL
important	NULL
in	NULL
promoting	NULL
cell	NULL
survival	NULL
because	NULL
of	NULL
their	NULL
role	NULL
in	NULL
promoting	NULL
NF-kB	NULL
activation	NULL
through	NULL
receptors	NULL
of	NULL
the	NULL
TNF	NULL
receptor	NULL
family	NULL
(	NULL
Beg	NULL
and	NULL
Baltimore	NULL
1996	NULL
;	NULL
Liu	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Van	NULL
Antwerp	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Wang	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
animals	NULL
with	NULL
a	NULL
targeted	NULL
TRAF3	NULL
disruption	NULL
(	NULL
Xu	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
and	NULL
trans-genic	NULL
mice	NULL
expressing	NULL
TRAF1	NULL
(	NULL
Speiser	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
have	NULL
both	NULL
been	NULL
reported	NULL
to	NULL
display	NULL
defects	NULL
in	NULL
lymphocyte	NULL
development	NULL
and	NULL
survival	NULL
.	NULL

In	NULL
this	NULL
report	NULL
we	NULL
describe	NULL
a	NULL
mechanism	NULL
by	NULL
which	NULL
signaling	NULL
through	NULL
CD30	NULL
can	NULL
both	NULL
promote	NULL
initial	NULL
cell	NULL
survival	NULL
while	NULL
at	NULL
the	NULL
same	NULL
time	NULL
setting	NULL
in	NULL
motion	NULL
a	NULL
signal-ing-dependent	NULL
mechanism	NULL
to	NULL
leave	NULL
the	NULL
cell	NULL
subsequently	NULL
more	NULL
susceptible	NULL
to	NULL
apoptosis	NULL
through	NULL
death	NULL
domain-containing	NULL
receptors	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
CD30	NULL
to	NULL
promote	NULL
cell	NULL
survival	NULL
is	NULL
dependent	NULL
on	NULL
its	NULL
ability	NULL
to	NULL
recruit	NULL
a	NULL
TRAP-dependent	NULL
signal	NULL
transduction	NULL
complex	NULL
(	NULL
Duckett	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

Now	NULL
,	NULL
we	NULL
show	NULL
that	NULL
the	NULL
recruitment	NULL
of	NULL
TRAF2	NULL
into	NULL
this	NULL
complex	NULL
results	NULL
in	NULL
the	NULL
signal-coupled	NULL
depletion	NULL
of	NULL
TRAF2	NULL
and	NULL
its	NULL
coassociated	NULL
signaling	NULL
molecule	NULL
TRAF1	NULL
.	NULL

This	NULL
depletion	NULL
in	NULL
TRAFZ	NULL
correlates	NULL
with	NULL
increased	NULL
cellular	NULL
sensitivity	NULL
to	NULL
cell	NULL
death	NULL
in	NULL
response	NULL
to	NULL
Degradation	NULL
of	NULL
TRAF2	NULL
by	NULL
CD30	NULL
TNFR1	NULL
signal	NULL
transduction	NULL
.	NULL

This	NULL
phenomenon	NULL
is	NULL
not	NULL
unique	NULL
to	NULL
CD30	NULL
signal	NULL
transduction	NULL
,	NULL
but	NULL
also	NULL
occurs	NULL
following	NULL
TNFR2	NULL
signal	NULL
transduction	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
central	NULL
role	NULL
of	NULL
the	NULL
TRAF2	NULL
signaling	NULL
complex	NULL
in	NULL
modulating	NULL
the	NULL
apoptotic	NULL
sensitivity	NULL
of	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
TNFR1	NULL
engagement	NULL
,	NULL
dominant-negative	NULL
TRAF2	NULL
was	NULL
found	NULL
to	NULL
directly	NULL
mimic	NULL
the	NULL
ability	NULL
of	NULL
CD30	NULL
signal	NULL
transduction	NULL
to	NULL
sensitize	NULL
cells	NULL
to	NULL
TNFR1-induced	NULL
apoptosis	NULL
.	NULL

Results	NULL
CD30	NULL
signaling	NULL
potentiates	NULL
TNFR	NULL
ediated	NULL
apoptosis	NULL
Recent	NULL
papers	NULL
have	NULL
shown	NULL
an	NULL
important	NULL
role	NULL
for	NULL
NF-kB	NULL
activation	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
cell	NULL
survival	NULL
(	NULL
Beg	NULL
and	NULL
Bal-tim	NULL
ore	NULL
1996	NULL
;	NULL
Liu	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Van	NULL
Antwerp	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Wang	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
,	NULL
and	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
CD30	NULL
is	NULL
a	NULL
potent	NULL
activator	NULL
of	NULL
NF-kB	NULL
(	NULL
Duckett	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

The	NULL
human	NULL
em	NULL
bryonic	NULL
kidney	NULL
cell	NULL
line	NULL
293	NULL
previously	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
express	NULL
TNFR1	NULL
but	NULL
not	NULL
TNFR2	NULL
(	NULL
Liu	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
C.S	NULL
.	NULL

Duckett	NULL
and	NULL
C.B	NULL
.	NULL

Thompson	NULL
,	NULL
unpubl	NULL
.	NULL
)	NULL

293	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
expression	NULL
vectors	NULL
encoding	NULL
green	NULL
fluorescent	NULL
protein	NULL
(	NULL
GFP	NULL
)	NULL
as	NULL
a	NULL
marker	NULL
of	NULL
transfection	NULL
,	NULL
together	NULL
with	NULL
a	NULL
plasmid	NULL
encoding	NULL
a	NULL
chimeric	NULL
protein	NULL
comprised	NULL
of	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
CD30	NULL
fused	NULL
to	NULL
the	NULL
extracellular	NULL
and	NULL
transmembrane	NULL
domains	NULL
of	NULL
CD28	NULL
.	NULL

This	NULL
chimeric	NULL
protein	NULL
is	NULL
expressed	NULL
on	NULL
the	NULL
cell	NULL
surface	NULL
as	NULL
a	NULL
constitutive	NULL
homodimer	NULL
,	NULL
and	NULL
this	NULL
dimerization	NULL
is	NULL
sufficient	NULL
to	NULL
initiate	NULL
CD30	NULL
signal	NULL
transduction	NULL
in	NULL
a	NULL
ligand-independent	NULL
manner	NULL
(	NULL
Duckett	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
this	NULL
protein	NULL
on	NULL
the	NULL
cell	NULL
surface	NULL
results	NULL
in	NULL
potent	NULL
NF-kB	NULL
activation	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
a	NULL
CD28	NULL
deletion	NULL
mutant	NULL
lacking	NULL
a	NULL
cytoplasmic	NULL
domain	NULL
(	NULL
CD28ATail	NULL
)	NULL
has	NULL
no	NULL
effect	NULL
on	NULL
NF-kB	NULL
activation	NULL
(	NULL
Duckett	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

The	NULL
present	NULL
experiments	NULL
were	NULL
initiated	NULL
to	NULL
determine	NULL
whether	NULL
CD30	NULL
signal	NULL
transduction	NULL
could	NULL
inhibit	NULL
the	NULL
ability	NULL
of	NULL
death	NULL
domain-containing	NULL
proteins	NULL
such	NULL
as	NULL
TNFR1	NULL
from	NULL
inducing	NULL
apoptosis	NULL
.	NULL

In	NULL
our	NULL
initial	NULL
experiments	NULL
,	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
recombinant	NULL
TNF-	NULL
«	NULL
12	NULL
hr	NULL
after	NULL
transfection	NULL
and	NULL
subsequently	NULL
evaluated	NULL
for	NULL
viability	NULL
by	NULL
nuclear	NULL
staining	NULL
with	NULL
4',6'-diamidino-2-phenylindole	NULL
(	NULL
DAPI	NULL
)	NULL
and	NULL
fluorescence	NULL
microscopy	NULL
.	NULL

Contrary	NULL
to	NULL
our	NULL
expectations	NULL
,	NULL
TNF-	NULL
«	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
viability	NULL
of	NULL
parental	NULL
293	NULL
cells	NULL
or	NULL
the	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
tailless	NULL
CD28	NULL
construct	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
70	NULL
%	NULL
of	NULL
the	NULL
CD30	NULL
transfectants	NULL
died	NULL
in	NULL
response	NULL
to	NULL
18	NULL
hr	NULL
of	NULL
TNF-a	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

The	NULL
nuclear	NULL
condensation	NULL
and	NULL
morphological	NULL
changes	NULL
as	NULL
observed	NULL
by	NULL
DAPI	NULL
staining	NULL
and	NULL
analysis	NULL
by	NULL
fluorescence	NULL
microscopy	NULL
were	NULL
indicative	NULL
of	NULL
apoptosis	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
cell	NULL
death	NULL
was	NULL
dependent	NULL
on	NULL
TNF-	NULL
«	NULL
,	NULL
as	NULL
the	NULL
CD30	NULL
chimera	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
TNF-a	NULL
had	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
viability	NULL
.	NULL

Flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
CD28-CD30	NULL
and	NULL
the	NULL
CD28AT	NULL
ail	NULL
vectors	NULL
surface	NULL
expression	NULL
revealed	NULL
very	NULL
similar	NULL
levels	NULL
of	NULL
CD28	NULL
surface	NULL
expression	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Previous	NULL
work	NULL
has	NULL
shown	NULL
that	NULL
CD30	NULL
signal	NULL
transduction	NULL
is	NULL
dependent	NULL
on	NULL
a	NULL
TRAP-binding	NULL
region	NULL
located	NULL
within	NULL
the	NULL
carboxy-terminal	NULL
36	NULL
amino	NULL
acids	NULL
of	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
(	NULL
Duckett	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
role	NULL
of	NULL
the	NULL
TRAF-binding	NULL
domain	NULL
of	NULL
CD30	NULL
in	NULL
the	NULL
poten-	NULL
GENES	NULL
&	NULL
DEVELOPMENT	NULL
2811	NULL
Duckett	NULL
and	NULL
Thompson	NULL
Figure	NULL
1	NULL
.	NULL

Potentiation	NULL
of	NULL
TNFR1-mediated	NULL
cell	NULL
death	NULL
by	NULL
constitutively	NULL
activated	NULL
chi	NULL
meric	NULL
CD30	NULL
.	NULL

(	NULL
4	NULL
)	NULL
293	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
a	NULL
vector	NULL
(	NULL
100	NULL
ng	NULL
)	NULL
encoding	NULL
GFP	NULL
together	NULL
A	NULL
eo	NULL
with	NULL
expression	NULL
vectors	NULL
(	NULL
1	NULL
ug	NULL
)	NULL
encoding	NULL
a	NULL
fu-	NULL
sion	NULL
between	NULL
CD28	NULL
and	NULL
CD30	NULL
,	NULL
a	NULL
mutated	NULL
CD28-CD30	NULL
vector	NULL
lacking	NULL
the	NULL
carboxy-ter-	NULL
minal	NULL
TRAF-binding	NULL
sites	NULL
(	NULL
ATraf	NULL
)	NULL
,	NULL
or	NULL
a	NULL
con-	NULL
%	NULL
60	NULL
60	NULL
%	NULL
o	NULL
Apoptotic	NULL
|	NULL
4	NULL
,	NULL
Cells	NULL
20	NULL
trol	NULL
CD28	NULL
mutant	NULL
lacking	NULL
a	NULL
cytoplasmic	NULL
tail	NULL
Apggltlgtlc	NULL
40	NULL
(	NULL
AT	NULL
ail	NULL
)	NULL
,	NULL
as	NULL
indicated	NULL
.	NULL

Twelve	NULL
hours	NULL
following	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
hu-	NULL
20	NULL
0	NULL
5	NULL
=	NULL
in	NULL
in	NULL
a	NULL
man	NULL
TNF-	NULL
«	NULL
(	NULL
200	NULL
U/m1	NULL
)	NULL
or	NULL
a	NULL
medium	NULL
control	NULL
5	NULL
a	NULL
<	NULL
zf	NULL
2	NULL
.	NULL

€	NULL
for	NULL
a	NULL
further	NULL
24	NULL
hr	NULL
,	NULL
and	NULL
viability	NULL
of	NULL
GFP-ex-	NULL
é	NULL
o	NULL
a	NULL
g	NULL
$	NULL
pressing	NULL
cells	NULL
was	NULL
determined	NULL
by	NULL
fluores-	NULL
TNF-ex	NULL
:	NULL
rary	NULL
g	NULL
“	NULL
a	NULL
9	NULL
cence	NULL
microscopy	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
coso	NULL
-	NULL
CDso	NULL
9	NULL
o	NULL
8	NULL
and	NULL
Methods	NULL
.	NULL

(	NULL
B	NULL
)	NULL
CD3O-enhanced	NULL
death	NULL
is	NULL
ATraf	NULL
8	NULL
blocked	NULL
by	NULL
apoptosis	NULL
inhibitors	NULL
.	NULL

293	NULL
cells	NULL
were	NULL
transfected	NULL
either	NULL
with	NULL
the	NULL
CD28	NULL
ATail	NULL
control	NULL
vector	NULL
(	NULL
Control	NULL
)	NULL
or	NULL
with	NULL
the	NULL
CD28-CD30	NULL
chimera	NULL
(	NULL
CD30	NULL
)	NULL
,	NULL
together	NULL
with	NULL
the	NULL
indicated	NULL
expression	NULL
vectors	NULL
.	NULL

Transfectants	NULL
were	NULL
stimulated	NULL
with	NULL
recom	NULL
binant	NULL
TNF-	NULL
«	NULL
and	NULL
viability	NULL
determined	NULL
as	NULL
described	NULL
above	NULL
and	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

tiation	NULL
of	NULL
TNF-	NULL
«	NULL
-induced	NULL
death	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
ability	NULL
of	NULL
a	NULL
mutant	NULL
of	NULL
CD28-CD30	NULL
chimera	NULL
that	NULL
lacks	NULL
the	NULL
TRAFP-binding	NULL
motifs	NULL
(	NULL
ATraf	NULL
)	NULL
to	NULL
potentiate	NULL
TNF-a	NULL
«	NULL
-m	NULL
ediated	NULL
death	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
vector	NULL
containing	NULL
the	NULL
full-length	NULL
CD30	NULL
tail	NULL
,	NULL
this	NULL
mutant	NULL
was	NULL
unable	NULL
to	NULL
induce	NULL
the	NULL
sensitivity	NULL
to	NULL
TNF-	NULL
«	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
contrary	NULL
to	NULL
our	NULL
expectations	NULL
,	NULL
these	NULL
data	NULL
suggest	NULL
that	NULL
CD30	NULL
can	NULL
potentiate	NULL
TNF-mediated	NULL
apoptosis	NULL
.	NULL

This	NULL
potentiation	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
TRAF-binding	NULL
sites	NULL
in	NULL
CD30	NULL
.	NULL

To	NULL
characterize	NULL
the	NULL
mechanism	NULL
of	NULL
cell	NULL
death	NULL
induced	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
CD30	NULL
signaling	NULL
and	NULL
expression	NULL
vectors	NULL
were	NULL
cotransfected	NULL
encoding	NULL
viral	NULL
proteins	NULL
that	NULL
are	NULL
known	NULL
to	NULL
block	NULL
apoptotic	NULL
cell	NULL
death	NULL
induced	NULL
by	NULL
mem	NULL
bers	NULL
of	NULL
the	NULL
caspase	NULL
family	NULL
of	NULL
cysteine	NULL
pro-teases	NULL
.	NULL

Expression	NULL
of	NULL
either	NULL
the	NULL
baculoviral	NULL
apoptotic	NULL
inhibitor	NULL
,	NULL
P35	NULL
(	NULL
Clem	NULL
et	NULL
al	NULL
.	NULL

1991	NULL
;	NULL
Bump	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
,	NULL
or	NULL
the	NULL
cowpox	NULL
virus	NULL
inhibitor	NULL
,	NULL
Crm	NULL
A	NULL
(	NULL
Gagliardini	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
;	NULL
Komiyama	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
)	NULL
,	NULL
completely	NULL
abrogated	NULL
the	NULL
cell	NULL
death	NULL
induced	NULL
by	NULL
TNF-a	NULL
plus	NULL
CD30	NULL
signaling	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
,	NULL
indicating	NULL
the	NULL
involvement	NULL
of	NULL
caspases	NULL
and	NULL
confirming	NULL
that	NULL
the	NULL
cell	NULL
death	NULL
was	NULL
caused	NULL
by	NULL
apoptosis	NULL
.	NULL

TRA	NULL
F2	NULL
is	NULL
degraded	NULL
upon	NULL
recruitment	NULL
to	NULL
CD30	NULL
The	NULL
experiments	NULL
described	NULL
above	NULL
suggested	NULL
a	NULL
role	NULL
for	NULL
the	NULL
TRAF	NULL
proteins	NULL
in	NULL
the	NULL
potentiation	NULL
of	NULL
TNFR1-mediated	NULL
death	NULL
.	NULL

Because	NULL
TRAF2	NULL
has	NULL
also	NULL
been	NULL
found	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
TNFR1-mediated	NULL
signaling	NULL
(	NULL
Hsu	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
,	NULL
we	NULL
sought	NULL
to	NULL
characterize	NULL
cellular	NULL
TRAFZ	NULL
.	NULL

Endogenous	NULL
TRAF2	NULL
protein	NULL
in	NULL
293	NULL
cells	NULL
was	NULL
not	NULL
detectable	NULL
by	NULL
immunoblot	NULL
analysis	NULL
with	NULL
commercially	NULL
available	NULL
TRAF2-spe-cific	NULL
antibodies	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
;	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
TRAF2	NULL
is	NULL
normally	NULL
expressed	NULL
at	NULL
levels	NULL
below	NULL
the	NULL
threshold	NULL
of	NULL
detection	NULL
in	NULL
this	NULL
cell	NULL
type	NULL
.	NULL

Therefore	NULL
,	NULL
a	NULL
mammalian	NULL
expression	NULL
vector	NULL
encoding	NULL
human	NULL
TRAF2	NULL
was	NULL
transfected	NULL
into	NULL
293	NULL
cells	NULL
together	NULL
with	NULL
either	NULL
the	NULL
chimeric	NULL
CD28	NULL
vector	NULL
containing	NULL
the	NULL
CD30	NULL
cytoplasmic	NULL
tail	NULL
,	NULL
or	NULL
the	NULL
CD28	NULL
vector	NULL
lacking	NULL
a	NULL
cytoplasmic	NULL
tail	NULL
.	NULL

Sur-prisingly	NULL
,	NULL
whereas	NULL
TRAF2	NULL
protein	NULL
was	NULL
easily	NULL
detected	NULL
in	NULL
2812	NULL
GENES	NULL
&	NULL
DEVELOPMENT	NULL
lysates	NULL
from	NULL
cells	NULL
cotransfected	NULL
with	NULL
the	NULL
TRAF2	NULL
plus	NULL
control	NULL
CD28	NULL
tailless	NULL
vectors	NULL
,	NULL
TRAF2	NULL
was	NULL
virtually	NULL
undetectable	NULL
when	NULL
cotransfected	NULL
with	NULL
the	NULL
CD28-CD30	NULL
chimera	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

This	NULL
effect	NULL
was	NULL
not	NULL
observed	NULL
when	NULL
TRAF2	NULL
was	NULL
coexpressed	NULL
with	NULL
a	NULL
CD30	NULL
vector	NULL
lacking	NULL
the	NULL
TRAF-binding	NULL
domains	NULL
.	NULL

High	NULL
levels	NULL
of	NULL
TRAF2	NULL
protein	NULL
were	NULL
also	NULL
detected	NULL
when	NULL
the	NULL
TRAF2	NULL
vector	NULL
was	NULL
transfected	NULL
alone	NULL
or	NULL
with	NULL
a	NULL
variety	NULL
of	NULL
additional	NULL
control	NULL
vectors	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
investigate	NULL
why	NULL
we	NULL
failed	NULL
to	NULL
detect	NULL
TRAF2	NULL
protein	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
TRAFZ	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
A	NULL
A	NULL
A	NULL
CD30	NULL
CD30	NULL
:	NULL
Tail	NULL
-	NULL
Tail	NULL
CD30	NULL
ATraf	NULL
TRAFR	NULL
-	NULL
0	NULL
4	NULL
%	NULL
04	NULL
%	NULL
0+	NULL
«	NULL
am	NULL
___	NULL
IP	NULL
le	NULL
B	NULL
.	NULL

.	NULL

.	NULL

--	NULL
TRAF2	NULL
«	NULL
--	NULL
28S	NULL
«	NULL
--	NULL
188	NULL
Figure	NULL
2	NULL
.	NULL

TRAF2	NULL
is	NULL
destabilized	NULL
by	NULL
CD30	NULL
.	NULL

293	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
TRAF2	NULL
and	NULL
CD28	NULL
chimera	NULL
expression	NULL
vectors	NULL
as	NULL
indicated	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Cells	NULL
were	NULL
lysed	NULL
18	NULL
hr	NULL
following	NULL
transfection	NULL
,	NULL
standardized	NULL
for	NULL
protein	NULL
levels	NULL
,	NULL
and	NULL
TRAF2	NULL
levels	NULL
were	NULL
detected	NULL
by	NULL
immunoblot	NULL
analysis	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Total	NULL
RN	NULL
A	NULL
was	NULL
prepared	NULL
from	NULL
an	NULL
equivalent	NULL
aliquot	NULL
of	NULL
cells	NULL
used	NULL
for	NULL
A	NULL
,	NULL
and	NULL
TRAF2	NULL
mRNA	NULL
was	NULL
evaluated	NULL
by	NULL
Northern	NULL
analysis	NULL
with	NULL
a	NULL
TRAF2	NULL
cDNA	NULL
probe	NULL
.	NULL

(	NULL
Bottom	NULL
)	NULL
An	NULL
ethidium	NULL
bromide-stained	NULL
agarose	NULL
gel	NULL
to	NULL
standardize	NULL
the	NULL
RNA	NULL
samples	NULL
;	NULL
(	NULL
fop	NULL
)	NULL
an	NULL
autoradiograph	NULL
of	NULL
the	NULL
TRAF2-probed	NULL
blot	NULL
.	NULL

chimeric	NULL
CD28-CD30	NULL
receptor	NULL
,	NULL
the	NULL
levels	NULL
of	NULL
TRAF2	NULL
RN	NULL
A	NULL
were	NULL
examined	NULL
by	NULL
Northern	NULL
analysis	NULL
.	NULL

The	NULL
amounts	NULL
of	NULL
TRAF2	NULL
RNA	NULL
were	NULL
similar	NULL
in	NULL
cells	NULL
cotransfected	NULL
with	NULL
the	NULL
ail	NULL
,	NULL
CD28-CD30	NULL
,	NULL
and	NULL
CD28-CD30ATraf	NULL
vectors	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
TRAF2	NULL
is	NULL
being	NULL
transcribed	NULL
at	NULL
equivalent	NULL
rates	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
the	NULL
CD28-CD30	NULL
receptor	NULL
.	NULL

The	NULL
failure	NULL
of	NULL
TRAF2	NULL
protein	NULL
to	NULL
accumulate	NULL
appears	NULL
to	NULL
be	NULL
mediated	NULL
by	NULL
post-tran-scriptional	NULL
mechanisms	NULL
.	NULL

CD30-induced	NULL
destabilization	NULL
of	NULL
TRA	NULL
F2	NULL
can	NULL
be	NULL
blocked	NULL
by	NULL
protease	NULL
inhibitors	NULL
To	NULL
further	NULL
characterize	NULL
the	NULL
process	NULL
of	NULL
CD3O0-induced	NULL
TRAF2	NULL
destabilization	NULL
,	NULL
a	NULL
panel	NULL
of	NULL
protease	NULL
inhibitors	NULL
were	NULL
tested	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
inhibit	NULL
CD3O0-induced	NULL
TRAF2	NULL
degradation	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Lactacystin	NULL
,	NULL
a	NULL
specific	NULL
inhibitor	NULL
of	NULL
the	NULL
ubiquitin-proteasome	NULL
pathway	NULL
(	NULL
Krap-pm	NULL
ann	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
,	NULL
was	NULL
unable	NULL
to	NULL
rescue	NULL
the	NULL
degradation	NULL
of	NULL
TRAF2	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
,	NULL
although	NULL
a	NULL
number	NULL
of	NULL
less	NULL
specific	NULL
compounds	NULL
such	NULL
as	NULL
E64	NULL
and	NULL
TLCK	NULL
were	NULL
able	NULL
to	NULL
inhibit	NULL
TRAF2	NULL
degradation	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
several	NULL
inhibitors	NULL
of	NULL
the	NULL
calpain	NULL
family	NULL
of	NULL
cysteine	NULL
proteases	NULL
were	NULL
found	NULL
to	NULL
efficiently	NULL
block	NULL
CD3O0-induced	NULL
TRAF2	NULL
degradation	NULL
.	NULL

The	NULL
calpains	NULL
are	NULL
a	NULL
family	NULL
of	NULL
cytoplasmic	NULL
,	NULL
calcium	NULL
-activated	NULL
cysteine	NULL
proteases	NULL
that	NULL
have	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
apoptosis	NULL
(	NULL
Squier	NULL
and	NULL
Cohen	NULL
1997	NULL
)	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
binding	NULL
of	NULL
TRAF2	NULL
to	NULL
the	NULL
cytoplasmic	NULL
tail	NULL
of	NULL
CD30	NULL
activates	NULL
a	NULL
protease	NULL
or	NULL
proteases	NULL
that	NULL
result	NULL
in	NULL
the	NULL
degradation	NULL
of	NULL
TRAFZ	NULL
.	NULL

Heterom	NULL
eric	NULL
com	NULL
plexes	NULL
containing	NULL
TRA	NULL
F2	NULL
are	NULL
also	NULL
degraded	NULL
upon	NULL
recruitment	NULL
to	NULL
CD30	NULL
It	NULL
has	NULL
previously	NULL
been	NULL
shown	NULL
that	NULL
TRAF1	NULL
,	NULL
TRAF2	NULL
,	NULL
and	NULL
TRAF3	NULL
can	NULL
be	NULL
directly	NULL
recruited	NULL
to	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
CD30	NULL
(	NULL
Ansieau	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Gedrich	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Lee	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

More	NULL
recently	NULL
,	NULL
three	NULL
additional	NULL
mem	NULL
bers	NULL
of	NULL
the	NULL
TRAF	NULL
family	NULL
have	NULL
also	NULL
been	NULL
identified	NULL
,	NULL
TRAF4	NULL
,	NULL
TRAF5	NULL
,	NULL
and	NULL
TRAF6	NULL
(	NULL
Tomasetto	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
;	NULL
Cao	NULL
et	NULL
al	NULL
.	NULL

Clee	NULL
2	NULL
E	NULL
E	NULL
&	NULL
>	NULL
go	NULL
g	NULL
a	NULL
o	NULL
Bot	NULL
t	NULL
5	NULL
x	NULL
op	NULL
2	NULL
=-	NULL
2	NULL
%	NULL
U	NULL
a	NULL
5	NULL
§	NULL
§	NULL
3	NULL
&	NULL
2	NULL
-	NULL
-o4	NULL
$	NULL
4	NULL
$	NULL
4	NULL
4	NULL
4	NULL
4	NULL
+	NULL
TRAFR	NULL
:	NULL
-	NULL
4	NULL
4	NULL
$	NULL
4	NULL
$	NULL
4	NULL
4	NULL
4	NULL
4+	NULL
4	NULL
I	NULL
1	NULL
¢	NULL
«	NULL
--	NULL
TRAF2	NULL
Figure	NULL
3	NULL
.	NULL

TRAF2	NULL
destabilization	NULL
can	NULL
be	NULL
blocked	NULL
by	NULL
protease	NULL
inhibitors	NULL
.	NULL

293	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
TRAF2	NULL
and	NULL
chimeric	NULL
CD28-CD30	NULL
expression	NULL
vectors	NULL
as	NULL
indicated	NULL
.	NULL

Parallel	NULL
wells	NULL
were	NULL
stimulated	NULL
36	NULL
hr	NULL
following	NULL
transfection	NULL
with	NULL
the	NULL
indicated	NULL
protease	NULL
inhibitors	NULL
each	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
50	NULL
uM	NULL
or	NULL
with	NULL
a	NULL
DMSO	NULL
solvent	NULL
control	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
0.001	NULL
%	NULL
,	NULL
and	NULL
lysates	NULL
were	NULL
prepared	NULL
48	NULL
hr	NULL
after	NULL
transfection	NULL
.	NULL

Standardized	NULL
extracts	NULL
were	NULL
examined	NULL
for	NULL
TRAF2	NULL
by	NULL
immunoblot	NULL
analysis	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Degradation	NULL
of	NULL
TRAF2	NULL
by	NULL
CD30	NULL
Table	NULL
1	NULL
.	NULL

Comparison	NULL
of	NULL
the	NULL
ability	NULL
of	NULL
CD30	NULL
to	NULL
bind	NULL
the	NULL
six	NULL
known	NULL
TRAF	NULL
proteins	NULL
with	NULL
its	NULL
degradative	NULL
properties	NULL
Binding	NULL
to	NULL
CD30	NULL
Degradation	NULL
by	NULL
CD30	NULL
TRAFI	NULL
+++	NULL
TRAF2	NULL
+++	NULL
+++	NULL
TRAF3	NULL
+++	NULL
+	NULL
TRAF4	NULL
-	NULL
TRAFS	NULL
+++	NULL
+	NULL
TRAFG	NULL
-	NULL
The	NULL
Cd30	NULL
binding	NULL
column	NULL
has	NULL
been	NULL
amalgamated	NULL
from	NULL
current	NULL
published	NULL
data	NULL
(	NULL
Ansieau	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Gedrich	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Lee	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
and	NULL
unpublished	NULL
data	NULL
.	NULL

The	NULL
degradation	NULL
by	NULL
CD30	NULL
column	NULL
summarizes	NULL
the	NULL
data	NULL
obtained	NULL
by	NULL
coexpression	NULL
of	NULL
CD28-CD30	NULL
chimeras	NULL
with	NULL
expression	NULL
vectors	NULL
encoding	NULL
wild-type	NULL
TRAF1	NULL
,	NULL
TRAF2	NULL
,	NULL
or	NULL
TRAF3	NULL
,	NULL
with	NULL
Myc	NULL
epitope-tagged	NULL
TRAF4	NULL
and	NULL
TRAFS5	NULL
,	NULL
or	NULL
with	NULL
FLAG	NULL
epitope-tagged	NULL
TRAF6	NULL
,	NULL
followed	NULL
by	NULL
immunoblot	NULL
analysis	NULL
,	NULL
as	NULL
indicated	NULL
.	NULL

(	NULL
+++	NULL
)	NULL
The	NULL
respective	NULL
TRAF	NULL
protein	NULL
was	NULL
reduced	NULL
>	NULL
80	NULL
%	NULL
by	NULL
coexpression	NULL
with	NULL
the	NULL
CD30	NULL
chimera	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
immunoblot	NULL
analysis	NULL
,	NULL
(	NULL
+	NULL
)	NULL
a	NULL
reduction	NULL
of	NULL
50	NULL
%	NULL
or	NULL
less	NULL
;	NULL
(	NULL
-	NULL
)	NULL
no	NULL
change	NULL
.	NULL

1996	NULL
;	NULL
Ishida	NULL
et	NULL
al	NULL
.	NULL

1996a	NULL
,	NULL
b	NULL
;	NULL
Nakano	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Aizawa	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
six	NULL
known	NULL
TRAF	NULL
proteins	NULL
were	NULL
assessed	NULL
for	NULL
their	NULL
abilities	NULL
to	NULL
be	NULL
degraded	NULL
upon	NULL
CD30	NULL
signaling	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
TRAF2	NULL
,	NULL
TRAF3	NULL
,	NULL
and	NULL
TRAFS	NULL
were	NULL
degraded	NULL
,	NULL
presumably	NULL
upon	NULL
binding	NULL
to	NULL
CD30	NULL
,	NULL
whereas	NULL
the	NULL
levels	NULL
of	NULL
TRAF1	NULL
,	NULL
TRAFA4	NULL
,	NULL
and	NULL
TRAF6	NULL
were	NULL
not	NULL
evidently	NULL
affected	NULL
by	NULL
coexpression	NULL
of	NULL
CD30	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

TRAFI	NULL
is	NULL
able	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
CD30	NULL
tail	NULL
,	NULL
but	NULL
was	NULL
not	NULL
degraded	NULL
,	NULL
suggesting	NULL
that	NULL
additional	NULL
determinants	NULL
may	NULL
be	NULL
present	NULL
in	NULL
TRAFs	NULL
2	NULL
,	NULL
3	NULL
,	NULL
and	NULL
5	NULL
which	NULL
confer	NULL
bind-ing-specific	NULL
degradation	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
1	NULL
,	NULL
TRAFl	NULL
was	NULL
not	NULL
degraded	NULL
by	NULL
CD30	NULL
signal	NULL
transduction	NULL
.	NULL

Because	NULL
TRAFl	NULL
and	NULL
TRAF	NULL
can	NULL
form	NULL
heterodimers	NULL
(	NULL
Rothe	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
,	NULL
1995b	NULL
)	NULL
,	NULL
we	NULL
tested	NULL
the	NULL
possibility	NULL
that	NULL
TRAF	NULL
might	NULL
function	NULL
to	NULL
stabilize	NULL
TRAF2	NULL
.	NULL

Expression	NULL
vectors	NULL
encoding	NULL
TRAFl	NULL
and	NULL
TRAF2	NULL
were	NULL
cotransfected	NULL
into	NULL
293	NULL
cells	NULL
together	NULL
with	NULL
either	NULL
the	NULL
CD28-CD30	NULL
vector	NULL
or	NULL
the	NULL
control	NULL
vector	NULL
lacking	NULL
a	NULL
cytoplasmic	NULL
tail	NULL
.	NULL

Cotransfection	NULL
of	NULL
TRAF1l	NULL
had	NULL
no	NULL
stabilizing	NULL
effect	NULL
on	NULL
TRAF2	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
whereas	NULL
expression	NULL
of	NULL
TRAFI	NULL
alone	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
CD30	NULL
,	NULL
coexpression	NULL
of	NULL
TRAFl	NULL
with	NULL
TRAFZ	NULL
resulted	NULL
in	NULL
the	NULL
almost	NULL
complete	NULL
disappearance	NULL
of	NULL
TRAF1	NULL
,	NULL
suggesting	NULL
that	NULL
recruitment	NULL
by	NULL
TRAF2	NULL
of	NULL
TRAFI	NULL
into	NULL
a	NULL
heteromeric	NULL
complex	NULL
with	NULL
CD30	NULL
resulted	NULL
in	NULL
degradation	NULL
of	NULL
both	NULL
TRAF	NULL
proteins	NULL
.	NULL

The	NULL
RING	NULL
finger	NULL
of	NULL
TRA	NULL
F2	NULL
is	NULL
required	NULL
for	NULL
CD30-m	NULL
ediated	NULL
degradation	NULL
Both	NULL
TRAF1	NULL
and	NULL
TRAF2	NULL
possess	NULL
similar	NULL
characteristics	NULL
of	NULL
recruitment	NULL
to	NULL
the	NULL
two	NULL
TRAP-binding	NULL
sites	NULL
in	NULL
CD30	NULL
(	NULL
Gedrich	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
,	NULL
but	NULL
as	NULL
shown	NULL
in	NULL
Figure	NULL
4A	NULL
,	NULL
TRAF	NULL
was	NULL
not	NULL
degraded	NULL
directly	NULL
by	NULL
CD30	NULL
signal	NULL
transduction	NULL
.	NULL

The	NULL
principal	NULL
structural	NULL
difference	NULL
between	NULL
TRAF1	NULL
and	NULL
TRAF2	NULL
is	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
RING	NULL
finger	NULL
domain	NULL
in	NULL
TRAF2	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
properties	NULL
of	NULL
a	NULL
mutant	NULL
version	NULL
of	NULL
GENES	NULL
&	NULL
DEVELOPMENT	NULL
2813	NULL
Duckett	NULL
and	NULL
Thompson	NULL
A	NULL
Atail	NULL
coo	NULL
TRAFI	NULL
:	NULL
40-00	NULL
%	NULL
#	NULL
-+	NULL
TRAFR	NULL
:	NULL
-	NULL
40	NULL
#	NULL
-	NULL
#	NULL
O+	NULL
(	NULL
tlk	NULL
(	NULL
wns	NULL
O	NULL
«	NULL
-	NULL
TRAF1	NULL
tee	NULL
.	NULL

-	NULL
Waite	NULL
*-	NULL
TRAF2	NULL
B	NULL
CD8	NULL
|	NULL
4	NULL
%	NULL
4+	NULL
-	NULL
Loge	NULL
2	NULL
-	NULL
0	NULL
-	NULL
4	NULL
-	NULL
#	NULL
-	NULL
04	NULL
%	NULL
-	NULL
0	NULL
4	NULL
&	NULL
0	NULL
40	NULL
-	NULL
0-0	NULL
#	NULL
$	NULL
%	NULL
TRAFZ	NULL
{	NULL
BT-§0k	NULL
-	NULL
0-0-0	NULL
40	NULL
4	NULL
40	NULL
%	NULL
CH	NULL
«	NULL
»	NULL
M	NULL
<	NULL
--	NULL
<	NULL
--	NULL
TRAFZ	NULL
(	NULL
1-501	NULL
)	NULL
cue	NULL
emm	NULL
(	NULL
k	NULL
<	NULL
>	NULL
4	NULL
Figure	NULL
4	NULL
.	NULL

Determinants	NULL
of	NULL
TRAF	NULL
degradation	NULL
.	NULL

(	NULL
4	NULL
)	NULL
293	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
expression	NULL
vectors	NULL
encoding	NULL
the	NULL
indicated	NULL
proteins	NULL
.	NULL

Lysates	NULL
were	NULL
prepared	NULL
48	NULL
hr	NULL
following	NULL
transfection	NULL
and	NULL
standardized	NULL
aliquots	NULL
were	NULL
subjected	NULL
to	NULL
immunoblot	NULL
analysis	NULL
with	NULL
a	NULL
polyclonal	NULL
antibody	NULL
to	NULL
TRAFI	NULL
(	NULL
fop	NULL
)	NULL
or	NULL
TRAF2	NULL
(	NULL
bottom	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
293	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
indicated	NULL
plasmids	NULL
,	NULL
including	NULL
either	NULL
wild-type	NULL
TRAF2	NULL
(	NULL
1-501	NULL
)	NULL
or	NULL
a	NULL
dominant-negative	NULL
mutant	NULL
(	NULL
87-501	NULL
)	NULL
lacking	NULL
a	NULL
functional	NULL
RING	NULL
finger	NULL
,	NULL
as	NULL
indicated	NULL
.	NULL

Cells	NULL
were	NULL
prepared	NULL
24	NULL
hr	NULL
follow	NULL
ing	NULL
transfection	NULL
and	NULL
analyzed	NULL
as	NULL
described	NULL
in	NULL
A	NULL
with	NULL
a	NULL
TRAF2	NULL
polyclonal	NULL
antibody	NULL
.	NULL

TRAF2	NULL
that	NULL
lacks	NULL
the	NULL
RING	NULL
finger	NULL
domain	NULL
were	NULL
examined	NULL
.	NULL

Deletion	NULL
of	NULL
the	NULL
amino-terminal	NULL
86	NULL
residues	NULL
of	NULL
TRAF2	NULL
has	NULL
previously	NULL
been	NULL
reported	NULL
to	NULL
disrupt	NULL
the	NULL
RING	NULL
finger	NULL
domain	NULL
of	NULL
TRAF2	NULL
without	NULL
diminishing	NULL
its	NULL
ability	NULL
to	NULL
bind	NULL
to	NULL
CD30	NULL
(	NULL
Gedrich	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

This	NULL
mutant	NULL
,	NULL
TRAF2	NULL
(	NULL
87-501	NULL
)	NULL
,	NULL
functions	NULL
in	NULL
a	NULL
dominant-negative	NULL
manner	NULL
to	NULL
inhibit	NULL
CD30-mediated	NULL
signaling	NULL
(	NULL
Duckett	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
4B	NULL
,	NULL
TRAF2	NULL
(	NULL
87-501	NULL
)	NULL
was	NULL
not	NULL
degraded	NULL
by	NULL
coexpression	NULL
with	NULL
CD30	NULL
,	NULL
whereas	NULL
in	NULL
control	NULL
transfections	NULL
,	NULL
the	NULL
level	NULL
of	NULL
full-length	NULL
TRAF2	NULL
was	NULL
dramatically	NULL
reduced	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
that	NULL
the	NULL
amino	NULL
terminus	NULL
of	NULL
TRAF2	NULL
,	NULL
which	NULL
contains	NULL
a	NULL
RING	NULL
finger	NULL
,	NULL
is	NULL
required	NULL
for	NULL
degradation	NULL
following	NULL
recruitment	NULL
to	NULL
the	NULL
cytoplasmic	NULL
tail	NULL
of	NULL
CD30	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
TRAF2	NULL
is	NULL
able	NULL
to	NULL
form	NULL
homodimers	NULL
,	NULL
as	NULL
well	NULL
as	NULL
heterodimers	NULL
with	NULL
TRAF1I	NULL
(	NULL
Rothe	NULL
et	NULL
al	NULL
.	NULL

1995b	NULL
)	NULL
.	NULL

Because	NULL
TRAF1	NULL
was	NULL
degraded	NULL
when	NULL
coexpressed	NULL
with	NULL
TRAF2	NULL
and	NULL
CD30	NULL
,	NULL
we	NULL
reasoned	NULL
that	NULL
the	NULL
dominant-negative	NULL
TRAF2	NULL
(	NULL
87-501	NULL
)	NULL
,	NULL
which	NULL
is	NULL
not	NULL
degraded	NULL
when	NULL
coexpressed	NULL
with	NULL
CD30	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
,	NULL
might	NULL
become	NULL
subject	NULL
to	NULL
degradation	NULL
if	NULL
coexpressed	NULL
with	NULL
full-length	NULL
TRAF2	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
4B	NULL
,	NULL
levels	NULL
of	NULL
cotransfected	NULL
full-length	NULL
TRAF2	NULL
and	NULL
truncated	NULL
TRAF2	NULL
(	NULL
87-501	NULL
)	NULL
were	NULL
dramatically	NULL
reduced	NULL
on	NULL
coexpression	NULL
with	NULL
the	NULL
CD28-CD30	NULL
chimera	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
a	NULL
complex	NULL
containing	NULL
both	NULL
the	NULL
full-length	NULL
and	NULL
the	NULL
truncated	NULL
(	NULL
87-501	NULL
)	NULL
forms	NULL
of	NULL
TRAF2	NULL
is	NULL
degraded	NULL
upon	NULL
recruitment	NULL
to	NULL
CD30	NULL
.	NULL

2814	NULL
GENES	NULL
&	NULL
DEVELOPMENT	NULL
Both	NULL
TRA	NULL
F-binding	NULL
sites	NULL
in	NULL
CD30	NULL
contribute	NULL
to	NULL
TRAF	NULL
degradation	NULL
Previously	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
TRAFZ2	NULL
can	NULL
bind	NULL
independently	NULL
to	NULL
either	NULL
of	NULL
two	NULL
5-7	NULL
residue	NULL
elements	NULL
in	NULL
CD30	NULL
(	NULL
domains	NULL
2A	NULL
and	NULL
2B	NULL
)	NULL
,	NULL
and	NULL
that	NULL
each	NULL
of	NULL
these	NULL
elements	NULL
are	NULL
independently	NULL
capable	NULL
of	NULL
recruiting	NULL
TRAF	NULL
proteins	NULL
and	NULL
inducing	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
(	NULL
Gedrich	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Duckett	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
additional	NULL
mutants	NULL
of	NULL
the	NULL
CD30	NULL
cytoplasmic	NULL
tail	NULL
were	NULL
tested	NULL
to	NULL
determine	NULL
which	NULL
of	NULL
the	NULL
two	NULL
TRAF-binding	NULL
elements	NULL
was	NULL
required	NULL
to	NULL
produce	NULL
destabilization	NULL
of	NULL
TRAFZ2	NULL
.	NULL

The	NULL
TRAF2	NULL
expression	NULL
vector	NULL
was	NULL
cotransfected	NULL
into	NULL
293	NULL
cells	NULL
together	NULL
with	NULL
chimeric	NULL
CD30	NULL
variants	NULL
lacking	NULL
the	NULL
TRAP-binding	NULL
domain	NULL
2A	NULL
only	NULL
,	NULL
2B	NULL
only	NULL
,	NULL
or	NULL
both	NULL
2A	NULL
and	NULL
2B	NULL
.	NULL

Individual	NULL
disruption	NULL
of	NULL
either	NULL
TRAF-binding	NULL
domain	NULL
2A	NULL
or	NULL
2B	NULL
resulted	NULL
in	NULL
mutants	NULL
that	NULL
induced	NULL
intermediate	NULL
levels	NULL
of	NULL
TRAF2	NULL
degradation	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

In	NULL
control	NULL
transfections	NULL
,	NULL
wild-type	NULL
CD30	NULL
resulted	NULL
in	NULL
the	NULL
almost	NULL
complete	NULL
loss	NULL
of	NULL
TRAF2	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
whereas	NULL
either	NULL
TRAP-binding	NULL
site	NULL
is	NULL
capable	NULL
of	NULL
partially	NULL
destabilizing	NULL
TRAF2	NULL
,	NULL
both	NULL
sites	NULL
are	NULL
required	NULL
for	NULL
maximal	NULL
destabilization	NULL
.	NULL

TNFR2	NULL
can	NULL
also	NULL
enhance	NULL
TNFR1	NULL
sensitivity	NULL
and	NULL
induce	NULL
TRAF	NULL
degradation	NULL
To	NULL
determine	NULL
whether	NULL
the	NULL
ability	NULL
to	NULL
heighten	NULL
sensitivity	NULL
to	NULL
TNFR1	NULL
signals	NULL
and	NULL
to	NULL
induce	NULL
the	NULL
degradation	NULL
of	NULL
TRAF2	NULL
is	NULL
a	NULL
unique	NULL
property	NULL
of	NULL
CD30	NULL
or	NULL
is	NULL
shared	NULL
by	NULL
other	NULL
TNF	NULL
receptor	NULL
family	NULL
members	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
properties	NULL
of	NULL
TNFR2Z	NULL
.	NULL

A	NULL
chimeric	NULL
vector	NULL
was	NULL
constructed	NULL
encoding	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
TNFR2	NULL
fused	NULL
to	NULL
the	NULL
extracellular	NULL
and	NULL
transmembrane	NULL
domains	NULL
of	NULL
CD28	NULL
.	NULL

Transfection	NULL
of	NULL
this	NULL
vector	NULL
into	NULL
293	NULL
cells	NULL
resulted	NULL
in	NULL
comparable	NULL
levels	NULL
of	NULL
both	NULL
surface	NULL
CD28	NULL
expression	NULL
and	NULL
NF-KB	NULL
induction	NULL
to	NULL
those	NULL
observed	NULL
after	NULL
transfection	NULL
of	NULL
the	NULL
CD28-CD30	NULL
chimera	NULL
or	NULL
the	NULL
control	NULL
CD28	NULL
vector	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Similar	NULL
to	NULL
the	NULL
results	NULL
found	NULL
with	NULL
the	NULL
CD28-CD30	NULL
protein	NULL
,	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
CD28-TNFR2	NULL
chimera	NULL
were	NULL
also	NULL
sensitized	NULL
to	NULL
TNFR1	NULL
<	NULL
0	NULL
®	NULL
oy	NULL
0	NULL
os	NULL
0	NULL
E	NULL
E	NULL
E	NULL
o	NULL
9	NULL
9	NULL
_-	NULL
To	NULL
G	NULL
G	NULL
8	NULL
0	NULL
«	NULL
<	NULL
0	NULL
40	NULL
«	NULL
4	NULL
o	NULL
-	NULL
9	NULL
o	NULL
o	NULL
=-	NULL
=	NULL
o	NULL
®	NULL
®	NULL
2	NULL
£	NULL
A	NULL
a	NULL
a	NULL
a	NULL
a	NULL
4	NULL
g-	NULL
U	NULL
QO	NULL
o	NULL
TRAFR	NULL
|-	NULL
004	NULL
#	NULL
0	NULL
#	NULL
0	NULL
#	NULL
%	NULL
omm	NULL
»	NULL
fl	NULL
aun	NULL
.	NULL

f-	NULL
TRAFZ	NULL
Figure	NULL
5	NULL
.	NULL

Both	NULL
TRAF-binding	NULL
sites	NULL
in	NULL
CD30	NULL
contribute	NULL
to	NULL
TRAF	NULL
degradation	NULL
.	NULL

293	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
TRAF2	NULL
and	NULL
CD28	NULL
chimera	NULL
expression	NULL
vectors	NULL
encoding	NULL
wild-type	NULL
CD30	NULL
,	NULL
tailless	NULL
CD28	NULL
(	NULL
ATail	NULL
)	NULL
,	NULL
or	NULL
mutated	NULL
proteins	NULL
lacking	NULL
both	NULL
TRAF-binding	NULL
motifs	NULL
(	NULL
A	NULL
dom	NULL
2	NULL
)	NULL
or	NULL
each	NULL
of	NULL
the	NULL
individual	NULL
TRAF-binding	NULL
domains	NULL
(	NULL
A	NULL
dom	NULL
2A	NULL
or	NULL
A	NULL
dom	NULL
2B	NULL
)	NULL
,	NULL
as	NULL
indicated	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
18	NULL
hr	NULL
following	NULL
transfection	NULL
and	NULL
standardized	NULL
for	NULL
protein	NULL
levels	NULL
,	NULL
and	NULL
TRAF2	NULL
levels	NULL
were	NULL
detected	NULL
by	NULL
immunoblot	NULL
analysis	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

80	NULL
A	NULL
60	NULL
%	NULL
Apoptotic	NULL
R	NULL
Cells	NULL
_	NULL
40	NULL
@	NULL
@	NULL
20	NULL
aA	NULL
4	NULL
TRAF	NULL
:	NULL
-	NULL
%	NULL
0	NULL
TNF-	NULL
«	NULL
:	NULL
-	NULL
+	NULL
-	NULL
o-p	NULL
o	NULL
-	NULL
f	NULL
ne	NULL
ATail	NULL
CD30	NULL
__	NULL
TNFR2	NULL
mediated	NULL
death	NULL
.	NULL

The	NULL
degree	NULL
of	NULL
sensitization	NULL
was	NULL
almost	NULL
identical	NULL
to	NULL
that	NULL
found	NULL
for	NULL
the	NULL
CD28-CD30	NULL
chim	NULL
era	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
cotransfection	NULL
of	NULL
CD28-TNFR2	NULL
with	NULL
TRAF2	NULL
also	NULL
induced	NULL
the	NULL
degradation	NULL
of	NULL
TRAF	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
,	NULL
revealing	NULL
that	NULL
the	NULL
enhancement	NULL
of	NULL
TNFR1	NULL
sensitivity	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
TRAF2	NULL
degradation	NULL
following	NULL
recruitment	NULL
to	NULL
the	NULL
receptor	NULL
,	NULL
is	NULL
not	NULL
restricted	NULL
to	NULL
CD30	NULL
,	NULL
but	NULL
can	NULL
occur	NULL
with	NULL
other	NULL
members	NULL
of	NULL
the	NULL
TNF	NULL
receptor	NULL
superfamily	NULL
.	NULL

Blockade	NULL
of	NULL
TRA	NULL
F2	NULL
signaling	NULL
can	NULL
potentiate	NULL
TNFR	NULL
ediated	NULL
death	NULL
The	NULL
experiments	NULL
described	NULL
above	NULL
show	NULL
that	NULL
the	NULL
recruitment	NULL
of	NULL
TRAF2	NULL
to	NULL
CD30	NULL
results	NULL
in	NULL
its	NULL
destabilization	NULL
by	NULL
a	NULL
mechanism	NULL
that	NULL
involves	NULL
proteolysis	NULL
.	NULL

Activation	NULL
of	NULL
TNFR1	NULL
has	NULL
also	NULL
been	NULL
shown	NULL
to	NULL
effect	NULL
the	NULL
recruitment	NULL
of	NULL
TRAF2	NULL
to	NULL
the	NULL
TNFR1	NULL
cytoplasmic	NULL
tail	NULL
,	NULL
by	NULL
virtue	NULL
of	NULL
a	NULL
TNFR1-TRADD-TRAF2	NULL
interaction	NULL
(	NULL
Hsu	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
,	NULL
and	NULL
this	NULL
recruitment	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
downstream	NULL
signals	NULL
,	NULL
notably	NULL
NF-kB	NULL
(	NULL
Rothe	NULL
et	NULL
al	NULL
.	NULL

1995b	NULL
)	NULL
and	NULL
JNK	NULL
(	NULL
Natoli	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
activation	NULL
.	NULL

One	NULL
consequence	NULL
of	NULL
TRAF2	NULL
degradation	NULL
by	NULL
CD30	NULL
might	NULL
be	NULL
to	NULL
inhibit	NULL
TRAF-mediated	NULL
signaling	NULL
by	NULL
TNFR1	NULL
.	NULL

To	NULL
test	NULL
this	NULL
possibility	NULL
,	NULL
293	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
dominant-negative	NULL
TRAF2	NULL
(	NULL
87-501	NULL
)	NULL
vector	NULL
,	NULL
treated	NULL
with	NULL
either	NULL
recombinant	NULL
TNF-	NULL
«	NULL
or	NULL
a	NULL
media	NULL
control	NULL
for	NULL
24	NULL
hr	NULL
,	NULL
and	NULL
assayed	NULL
for	NULL
viability	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
7	NULL
,	NULL
similar	NULL
to	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
constitutively	NULL
active	NULL
CD30	NULL
chimera	NULL
,	NULL
expression	NULL
of	NULL
dom	NULL
inant-negative	NULL
TRAF2	NULL
greatly	NULL
sensitized	NULL
the	NULL
cells	NULL
TNF-a	NULL
«	NULL
-mediated	NULL
death	NULL
,	NULL
suggesting	NULL
that	NULL
blocking	NULL
the	NULL
ability	NULL
of	NULL
TRAF	NULL
proteins	NULL
to	NULL
participate	NULL
in	NULL
TNFR1-dependent	NULL
signal	NULL
transduction	NULL
can	NULL
enhance	NULL
the	NULL
sensitivity	NULL
to	NULL
TNF-a	NULL
@	NULL
.	NULL

CD30	NULL
signaling	NULL
abrogates	NULL
the	NULL
induction	NULL
of	NULL
NF-kB	NULL
by	NULL
TNF-a	NULL
Previous	NULL
studies	NULL
have	NULL
found	NULL
that	NULL
the	NULL
induction	NULL
of	NULL
NF-kB	NULL
can	NULL
confer	NULL
protection	NULL
from	NULL
TNF-a	NULL
«	NULL
-mediated	NULL
death	NULL
(	NULL
Beg	NULL
#	NULL
CD30	NULL
=	NULL
TNFR2	NULL
Degradation	NULL
of	NULL
TRAF2	NULL
by	NULL
CD30	NULL
Figure	NULL
6	NULL
.	NULL

TNFR2	NULL
can	NULL
enhance	NULL
TNFR1	NULL
sensitivity	NULL
and	NULL
induces	NULL
TRAF2	NULL
degradation	NULL
.	NULL

(	NULL
4	NULL
)	NULL
293	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
indicated	NULL
CD28	NULL
chimeric	NULL
vectors	NULL
(	NULL
1	NULL
ug	NULL
)	NULL
,	NULL
along	NULL
with	NULL
a	NULL
GEFP	NULL
vector	NULL
(	NULL
100	NULL
ng	NULL
)	NULL
,	NULL
exactly	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Transfectants	NULL
were	NULL
stimulated	NULL
with	NULL
TNF-	NULL
«	NULL
(	NULL
200	NULL
U/ml	NULL
)	NULL
and	NULL
cell	NULL
viability	NULL
was	NULL
determined	NULL
by	NULL
DAPI	NULL
staining	NULL
and	NULL
fluorescence	NULL
microscopy	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

(	NULL
B	NULL
)	NULL
293	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
TRAF2	NULL
expression	NULL
vector	NULL
along	NULL
with	NULL
the	NULL
indicated	NULL
chimeric	NULL
vectors	NULL
.	NULL

Twelve	NULL
hours	NULL
following	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
either	NULL
mock	NULL
treated	NULL
or	NULL
treated	NULL
with	NULL
human	NULL
TNF-	NULL
«	NULL
(	NULL
200	NULL
U/ml	NULL
)	NULL
as	NULL
indicated	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
24	NULL
hr	NULL
following	NULL
transfection	NULL
,	NULL
standardized	NULL
by	NULL
protein	NULL
content	NULL
and	NULL
TRAF2	NULL
was	NULL
detected	NULL
by	NULL
immunoblot	NULL
analysis	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

ATall	NULL
+	NULL
TNF-q	NULL
a	NULL
a	NULL
and	NULL
Baltimore	NULL
1996	NULL
;	NULL
Liu	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Van	NULL
Antwerp	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Wang	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

Because	NULL
TRAF2	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
play	NULL
an	NULL
integral	NULL
role	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
NF-kB	NULL
by	NULL
TNFR	NULL
1	NULL
(	NULL
Hsu	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
cells	NULL
to	NULL
respond	NULL
to	NULL
TNF-a	NULL
following	NULL
prolonged	NULL
CD30	NULL
signal	NULL
transduction	NULL
was	NULL
examined	NULL
.	NULL

Cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
chimeric	NULL
CD28-CD30	NULL
plasmid	NULL
or	NULL
with	NULL
the	NULL
tailless	NULL
control	NULL
plas-mid	NULL
.	NULL

Forty-eight	NULL
hours	NULL
later	NULL
,	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
TNF-	NULL
«	NULL
and	NULL
then	NULL
evaluated	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
levels	NULL
by	NULL
luciferase	NULL
reporter	NULL
gene	NULL
assays	NULL
.	NULL

Cells	NULL
transfected	NULL
with	NULL
the	NULL
CD28-CD30	NULL
plasmid	NULL
were	NULL
unable	NULL
to	NULL
induce	NULL
NF-kB	NULL
in	NULL
response	NULL
to	NULL
TNF-	NULL
«	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
,	NULL
whereas	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
control	NULL
plasmid	NULL
induced	NULL
NF-	NULL
«	NULL
B-dependent	NULL
reporter	NULL
gene	NULL
activity	NULL
in	NULL
response	NULL
to	NULL
TNF-	NULL
«	NULL
.	NULL

Discussion	NULL
A	NULL
subfamily	NULL
of	NULL
TNF	NULL
receptor	NULL
superfamily	NULL
members	NULL
has	NULL
recently	NULL
been	NULL
defined	NULL
that	NULL
shares	NULL
the	NULL
common	NULL
ability	NULL
to	NULL
80	NULL
60	NULL
%	NULL
Apoptotic	NULL
Cells	NULL
40	NULL
20	NULL
0	NULL
TNF-a	NULL
:	NULL
-o	NULL
+00	NULL
-	NULL
o	NULL
$	NULL
O-	NULL
+	NULL
ATail	NULL
_	NULL
TRAF2	NULL
CD30	NULL
(	NULL
87-501	NULL
)	NULL
Figure	NULL
7	NULL
.	NULL

Dominant-negative	NULL
TRAF2	NULL
can	NULL
potentiate	NULL
TNFR1-mediated	NULL
death	NULL
.	NULL

293	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
100	NULL
ng	NULL
of	NULL
GFP	NULL
plasmid	NULL
,	NULL
together	NULL
with	NULL
1	NULL
ug	NULL
of	NULL
the	NULL
indicated	NULL
plasmids	NULL
,	NULL
and	NULL
either	NULL
mock	NULL
treated	NULL
or	NULL
treated	NULL
with	NULL
human	NULL
TNF-	NULL
«	NULL
(	NULL
200	NULL
U/m1	NULL
)	NULL
,	NULL
and	NULL
cell	NULL
viability	NULL
was	NULL
determ	NULL
ined	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

GENES	NULL
&	NULL
DEVELOPMENT	NULL
2815	NULL
Duckett	NULL
and	NULL
Thompson	NULL
200	NULL
150	NULL
Inchoase	NULL
100	NULL
50	NULL
o	NULL
Control	NULL
CD30	NULL
Figure	NULL
8	NULL
.	NULL

CD30	NULL
signaling	NULL
abrogates	NULL
NF-	NULL
«	NULL
B	NULL
induction	NULL
by	NULL
TNF-	NULL
«	NULL
.	NULL

293	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
50	NULL
ng	NULL
each	NULL
of	NULL
«	NULL
B-luciferase	NULL
reporter	NULL
plasmid	NULL
and	NULL
B-galactosidase	NULL
plasmid	NULL
,	NULL
along	NULL
with	NULL
100	NULL
ng	NULL
of	NULL
either	NULL
CD28-CD30	NULL
vector	NULL
or	NULL
tailless	NULL
CD28	NULL
as	NULL
indicated	NULL
.	NULL

Cells	NULL
were	NULL
stimulated	NULL
with	NULL
TNF-	NULL
«	NULL
48	NULL
hr	NULL
following	NULL
transfection	NULL
,	NULL
and	NULL
incubated	NULL
further	NULL
for	NULL
10	NULL
hr	NULL
prior	NULL
to	NULL
harvest	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
presented	NULL
as	NULL
the	NULL
percentage	NULL
increase	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
of	NULL
TNF-	NULL
«	NULL
-treated	NULL
samples	NULL
over	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
reporter	NULL
plasmid	NULL
in	NULL
mock-treated	NULL
cells	NULL
.	NULL

Luciferase	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

initiate	NULL
signal	NULL
transduction	NULL
through	NULL
TRAF	NULL
proteins	NULL
,	NULL
leading	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
NF-KB	NULL
.	NULL

In	NULL
most	NULL
cases	NULL
,	NULL
this	NULL
promotes	NULL
cell	NULL
survival	NULL
.	NULL

These	NULL
same	NULL
receptors	NULL
,	NULL
however	NULL
,	NULL
have	NULL
been	NULL
implicated	NULL
in	NULL
cell	NULL
death	NULL
,	NULL
under	NULL
some	NULL
circum-stances	NULL
.	NULL

Unlike	NULL
TNFR1	NULL
,	NULL
Fas	NULL
and	NULL
DR3/Wsl/	NULL
Apo-3	NULL
(	NULL
Tartaglia	NULL
et	NULL
al	NULL
.	NULL

1993	NULL
;	NULL
Takahashi	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
;	NULL
Chinnaiyan	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Kitson	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Marsters	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Pan	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
,	NULL
which	NULL
contain	NULL
death	NULL
domains	NULL
capable	NULL
of	NULL
inducing	NULL
apoptosis	NULL
through	NULL
the	NULL
recruitment	NULL
and	NULL
activation	NULL
of	NULL
caspases	NULL
(	NULL
Nagata	NULL
1996	NULL
)	NULL
,	NULL
it	NULL
is	NULL
not	NULL
known	NULL
how	NULL
these	NULL
receptors	NULL
can	NULL
induce	NULL
apoptosis	NULL
.	NULL

As	NULL
an	NULL
example	NULL
,	NULL
CD30	NULL
appears	NULL
to	NULL
play	NULL
dual	NULL
roles	NULL
in	NULL
the	NULL
cell	NULL
.	NULL

CD30	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
promote	NULL
the	NULL
development	NULL
and	NULL
differentiation	NULL
of	NULL
T	NULL
helper	NULL
type	NULL
2	NULL
(	NULL
Th2	NULL
)	NULL
cells	NULL
(	NULL
Del	NULL
Prete	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
,	NULL
and	NULL
,	NULL
therefore	NULL
,	NULL
has	NULL
been	NULL
associated	NULL
with	NULL
cellular	NULL
survival	NULL
and	NULL
proliferation	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
other	NULL
findings	NULL
have	NULL
implicated	NULL
CD30	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
cell	NULL
death	NULL
(	NULL
Lee	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

Disruption	NULL
of	NULL
murine	NULL
CD30	NULL
by	NULL
homologous	NULL
recombination	NULL
(	NULL
Amakawa	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
has	NULL
implicated	NULL
a	NULL
role	NULL
for	NULL
this	NULL
receptor	NULL
in	NULL
thymic	NULL
negative	NULL
selection	NULL
.	NULL

Similar	NULL
to	NULL
CD30	NULL
,	NULL
TNFR2	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
exert	NULL
both	NULL
pro-survival	NULL
and	NULL
pro-death	NULL
effects	NULL
on	NULL
the	NULL
cell	NULL
.	NULL

TNFR2	NULL
can	NULL
confer	NULL
protection	NULL
from	NULL
cell	NULL
death	NULL
,	NULL
and	NULL
cellular	NULL
proliferation	NULL
(	NULL
Rothe	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
TNFR2	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
play	NULL
a	NULL
role	NULL
in	NULL
apoptosis	NULL
of	NULL
mature	NULL
T	NULL
cells	NULL
(	NULL
Zheng	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
.	NULL

Several	NULL
models	NULL
have	NULL
been	NULL
proposed	NULL
to	NULL
account	NULL
for	NULL
the	NULL
opposing	NULL
properties	NULL
of	NULL
TNFR2	NULL
.	NULL

The	NULL
rapid	NULL
association/dissociation	NULL
kinetics	NULL
of	NULL
TNFR2	NULL
for	NULL
its	NULL
2816	NULL
GENES	NULL
&	NULL
DEVELOPMENT	NULL
ligand	NULL
have	NULL
led	NULL
to	NULL
the	NULL
ligand	NULL
passing	NULL
hypothesis	NULL
(	NULL
Tartaglia	NULL
et	NULL
al	NULL
.	NULL

1993	NULL
)	NULL
,	NULL
in	NULL
which	NULL
TNFR2	NULL
is	NULL
postulated	NULL
to	NULL
recruit	NULL
TNF-	NULL
«	NULL
and	NULL
provide	NULL
a	NULL
source	NULL
of	NULL
ligand	NULL
for	NULL
TNFR1	NULL
,	NULL
thus	NULL
suggesting	NULL
a	NULL
passive	NULL
role	NULL
for	NULL
TNFR2	NULL
in	NULL
signaling	NULL
.	NULL

Grell	NULL
and	NULL
coworkers	NULL
have	NULL
suggested	NULL
that	NULL
TNFR2	NULL
specifically	NULL
binds	NULL
mem	NULL
brane-associated	NULL
TNF-	NULL
«	NULL
and	NULL
thereby	NULL
induces	NULL
cell	NULL
death	NULL
(	NULL
Grell	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
,	NULL
although	NULL
this	NULL
does	NULL
not	NULL
necessarily	NULL
exclude	NULL
the	NULL
ligand-passing	NULL
model	NULL
.	NULL

More	NULL
recently	NULL
,	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
TNFR2	NULL
is	NULL
required	NULL
for	NULL
the	NULL
potentiation	NULL
of	NULL
TNFR1-mediated	NULL
death	NULL
(	NULL
Weiss	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
cooperative	NULL
signaling	NULL
through	NULL
these	NULL
receptors	NULL
,	NULL
perhaps	NULL
by	NULL
li-gand-induced	NULL
oligomerization	NULL
,	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
this	NULL
cooperative	NULL
response	NULL
.	NULL

The	NULL
experiments	NULL
described	NULL
here	NULL
m	NULL
ay	NULL
provide	NULL
an	NULL
explanation	NULL
for	NULL
the	NULL
dual	NULL
effects	NULL
of	NULL
CD30	NULL
and	NULL
TNFR2	NULL
.	NULL

Stimulation	NULL
of	NULL
293	NULL
cells	NULL
with	NULL
TNF-	NULL
«	NULL
alone	NULL
did	NULL
not	NULL
induce	NULL
a	NULL
significant	NULL
degree	NULL
of	NULL
cell	NULL
death	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Although	NULL
293	NULL
cells	NULL
contain	NULL
the	NULL
product	NULL
of	NULL
the	NULL
antiapoptotic	NULL
adenovirus	NULL
gene	NULL
E1B	NULL
19K	NULL
,	NULL
which	NULL
may	NULL
function	NULL
to	NULL
raise	NULL
the	NULL
cellular	NULL
apoptotic	NULL
threshold	NULL
,	NULL
constitutive	NULL
signal	NULL
transduction	NULL
mediated	NULL
either	NULL
by	NULL
a	NULL
CD28-CD30	NULL
or	NULL
a	NULL
CD28-TNFR2	NULL
chimera	NULL
potentiated	NULL
TNFR1-induced	NULL
cell	NULL
death	NULL
(	NULL
Figs	NULL
.	NULL

1A	NULL
and	NULL
6A	NULL
)	NULL
.	NULL

The	NULL
TRAP-binding	NULL
domain	NULL
in	NULL
CD30	NULL
was	NULL
required	NULL
for	NULL
potentiation	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
,	NULL
and	NULL
other	NULL
reports	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
TRAP-binding	NULL
element	NULL
in	NULL
TNFR2	NULL
is	NULL
required	NULL
for	NULL
sensitization	NULL
by	NULL
this	NULL
receptor	NULL
(	NULL
Weiss	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
CD30	NULL
signaling	NULL
functions	NULL
by	NULL
the	NULL
same	NULL
mechanism	NULL
as	NULL
TNFR2	NULL
to	NULL
potentiate	NULL
TNFR1-mediated	NULL
death	NULL
.	NULL

Because	NULL
CD30	NULL
and	NULL
TNFR2	NULL
are	NULL
norm	NULL
ally	NULL
activated	NULL
by	NULL
independent	NULL
ligands	NULL
,	NULL
this	NULL
raises	NULL
the	NULL
possibility	NULL
that	NULL
other	NULL
mem	NULL
bers	NULL
of	NULL
the	NULL
TNF	NULL
receptor	NULL
superfam	NULL
ily	NULL
that	NULL
utilize	NULL
the	NULL
TRAF	NULL
signaling	NULL
pathway	NULL
may	NULL
also	NULL
function	NULL
to	NULL
potentiate	NULL
TNFR1-mediated	NULL
death	NULL
by	NULL
a	NULL
similar	NULL
mechanism..	NULL

It	NULL
is	NULL
formally	NULL
possible	NULL
that	NULL
the	NULL
apoptotic	NULL
properties	NULL
of	NULL
CD30	NULL
and	NULL
TNFR2	NULL
are	NULL
mediated	NULL
by	NULL
recruitment	NULL
and	NULL
activation	NULL
of	NULL
caspases	NULL
,	NULL
for	NULL
example	NULL
,	NULL
through	NULL
the	NULL
formation	NULL
of	NULL
a	NULL
TRAF2-TRADD-FADD-caspase	NULL
complex	NULL
.	NULL

Because	NULL
CD30	NULL
was	NULL
unable	NULL
to	NULL
induce	NULL
cell	NULL
death	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
a	NULL
TNFR1	NULL
signal	NULL
,	NULL
however	NULL
,	NULL
it	NULL
is	NULL
more	NULL
likely	NULL
that	NULL
CD30	NULL
functions	NULL
as	NULL
a	NULL
cofactor	NULL
to	NULL
potentiate	NULL
the	NULL
cytotoxic	NULL
effects	NULL
of	NULL
TNFR1	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
2A	NULL
,	NULL
we	NULL
found	NULL
that	NULL
TRAF2	NULL
protein	NULL
was	NULL
alm	NULL
ost	NULL
completely	NULL
degraded	NULL
by	NULL
activation	NULL
of	NULL
CD30-mediated	NULL
,	NULL
TRAF-dependent	NULL
signals	NULL
.	NULL

This	NULL
destabilization	NULL
did	NULL
not	NULL
occur	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
,	NULL
but	NULL
could	NULL
be	NULL
inhibited	NULL
by	NULL
several	NULL
protease	NULL
inhibitors	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
,	NULL
suggesting	NULL
the	NULL
involvement	NULL
of	NULL
a	NULL
proteolytic	NULL
program	NULL
that	NULL
specifically	NULL
degrades	NULL
TRAFZ	NULL
.	NULL

Degradation	NULL
of	NULL
TRAF2	NULL
could	NULL
be	NULL
induced	NULL
by	NULL
recruitment	NULL
to	NULL
either	NULL
of	NULL
the	NULL
two	NULL
TRAP-binding	NULL
domains	NULL
in	NULL
CD30	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
that	NULL
have	NULL
previously	NULL
been	NULL
identified	NULL
(	NULL
Gedrich	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

Degradation	NULL
could	NULL
also	NULL
be	NULL
induced	NULL
by	NULL
recruitment	NULL
to	NULL
TNFR2	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
,	NULL
suggesting	NULL
a	NULL
shared	NULL
pathway	NULL
.	NULL

Signal	NULL
transduction	NULL
mediated	NULL
by	NULL
CD30	NULL
and	NULL
TNFR2	NULL
utilizes	NULL
TRAF2	NULL
,	NULL
which	NULL
subsequently	NULL
leads	NULL
to	NULL
NF-KB	NULL
activation	NULL
.	NULL

This	NULL
activation	NULL
has	NULL
been	NULL
previously	NULL
shown	NULL
to	NULL
involve	NULL
the	NULL
degradation	NULL
of	NULL
IKB	NULL
by	NULL
the	NULL
ubiquitin-proteasome	NULL
pathway	NULL
(	NULL
Palom	NULL
bella	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
;	NULL
Chen	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
,	NULL
1996	NULL
;	NULL
Henkel	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
;	NULL
DiDonato	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Hateboer	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

Signaling	NULL
through	NULL
endogenous	NULL
TNFR1	NULL
,	NULL
however	NULL
,	NULL
which	NULL
also	NULL
results	NULL
in	NULL
the	NULL
TRAF2-me-diated	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
Hsu	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
and	NULL
induces	NULL
the	NULL
degradation	NULL
of	NULL
IxB	NULL
(	NULL
Chen	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
;	NULL
DiDonato	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
;	NULL
Henkel	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
,	NULL
did	NULL
not	NULL
result	NULL
in	NULL
the	NULL
destabilization	NULL
of	NULL
TRAF2	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

Although	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
ectopically	NULL
expressed	NULL
,	NULL
activated	NULL
TNFR1	NULL
might	NULL
also	NULL
induce	NULL
TRAF2	NULL
degradation	NULL
,	NULL
these	NULL
findings	NULL
suggest	NULL
that	NULL
the	NULL
determinants	NULL
of	NULL
TRAF2	NULL
degradation	NULL
are	NULL
distinct	NULL
from	NULL
those	NULL
of	NULL
IxB	NULL
degradation	NULL
.	NULL

Signaling	NULL
through	NULL
CD30	NULL
does	NULL
not	NULL
induce	NULL
a	NULL
general	NULL
degradation	NULL
of	NULL
all	NULL
TRAF	NULL
proteins	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
binding	NULL
of	NULL
TRAF	NULL
proteins	NULL
to	NULL
CD30	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
induce	NULL
degradation	NULL
,	NULL
because	NULL
TRAF	NULL
binds	NULL
directly	NULL
to	NULL
CD30	NULL
(	NULL
Gedrich	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
but	NULL
is	NULL
not	NULL
degraded	NULL
.	NULL

One	NULL
difference	NULL
that	NULL
may	NULL
account	NULL
for	NULL
this	NULL
is	NULL
the	NULL
absence	NULL
of	NULL
a	NULL
RING	NULL
finger	NULL
domain	NULL
in	NULL
TRAF1	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
4B	NULL
,	NULL
the	NULL
disruption	NULL
of	NULL
the	NULL
RING	NULL
finger	NULL
of	NULL
TRAF2	NULL
abrogated	NULL
degradation	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
RING	NULL
finger	NULL
of	NULL
TRAF2	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
destabilization	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
RING	NULL
finger	NULL
has	NULL
also	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
required	NULL
for	NULL
NF-KB	NULL
activation	NULL
by	NULL
TRAF2	NULL
(	NULL
Rothe	NULL
et	NULL
al	NULL
.	NULL

1995b	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
RING	NULL
finger	NULL
may	NULL
be	NULL
required	NULL
both	NULL
for	NULL
protein-protein	NULL
interactions	NULL
with	NULL
downstream	NULL
signaling	NULL
components	NULL
as	NULL
well	NULL
as	NULL
for	NULL
the	NULL
targeting	NULL
of	NULL
TRAF2	NULL
for	NULL
degradation	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
TRAF2	NULL
(	NULL
87-501	NULL
)	NULL
mutant	NULL
is	NULL
not	NULL
subject	NULL
to	NULL
degradation	NULL
and	NULL
so	NULL
might	NULL
block	NULL
NF-KB	NULL
activation	NULL
by	NULL
competitively	NULL
binding	NULL
to	NULL
CD30	NULL
,	NULL
thereby	NULL
preventing	NULL
recruitment	NULL
of	NULL
endogenous	NULL
TRAF2	NULL
to	NULL
CD30	NULL
.	NULL

The	NULL
construction	NULL
of	NULL
fusion	NULL
proteins	NULL
between	NULL
TRAFl	NULL
and	NULL
TRAF2	NULL
,	NULL
however	NULL
,	NULL
have	NULL
so	NULL
far	NULL
failed	NULL
to	NULL
generate	NULL
a	NULL
chimeric	NULL
TRAFI-TRAF2	NULL
molecule	NULL
that	NULL
could	NULL
be	NULL
degraded	NULL
by	NULL
CD30	NULL
signaling	NULL
(	NULL
C.S	NULL
.	NULL

Duckett	NULL
and	NULL
C.B	NULL
.	NULL

Thompson	NULL
,	NULL
unpubl	NULL
.	NULL
)	NULL

,	NULL
suggesting	NULL
that	NULL
additional	NULL
determinants	NULL
in	NULL
TRAF2	NULL
may	NULL
also	NULL
be	NULL
required	NULL
.	NULL

Also	NULL
noteworthy	NULL
is	NULL
the	NULL
observation	NULL
that	NULL
TRAF1l	NULL
can	NULL
be	NULL
degraded	NULL
when	NULL
coexpressed	NULL
with	NULL
TRAF2	NULL
.	NULL

This	NULL
finding	NULL
suggests	NULL
that	NULL
the	NULL
degradation	NULL
of	NULL
TRAF2	NULL
can	NULL
extend	NULL
to	NULL
additional	NULL
molecules	NULL
associated	NULL
with	NULL
TRAF2	NULL
,	NULL
and	NULL
this	NULL
might	NULL
also	NULL
be	NULL
the	NULL
case	NULL
for	NULL
factors	NULL
unrelated	NULL
to	NULL
the	NULL
TRAFs	NULL
such	NULL
as	NULL
the	NULL
c-IAPs	NULL
,	NULL
TANK/I-TRAF	NULL
,	NULL
Nik	NULL
,	NULL
A20	NULL
and	NULL
TRIP	NULL
,	NULL
all	NULL
of	NULL
which	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
associate	NULL
directly	NULL
with	NULL
TRAF2	NULL
(	NULL
Rothe	NULL
et	NULL
al	NULL
.	NULL

1995a	NULL
,	NULL
1996	NULL
;	NULL
Cheng	NULL
and	NULL
Baltimore	NULL
1996	NULL
;	NULL
Song	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Lee	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
;	NULL
Malinin	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

TRAF2	NULL
is	NULL
a	NULL
signaling	NULL
intermediate	NULL
that	NULL
is	NULL
also	NULL
utilized	NULL
by	NULL
TNFR1	NULL
(	NULL
Hsu	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

Whereas	NULL
TRAF2	NULL
can	NULL
bind	NULL
directly	NULL
to	NULL
the	NULL
cytoplasmic	NULL
domains	NULL
of	NULL
TNFR2	NULL
and	NULL
CD30	NULL
,	NULL
it	NULL
is	NULL
recruited	NULL
indirectly	NULL
to	NULL
TNFR1	NULL
through	NULL
a	NULL
TNFR1-TRADD-TRAF2	NULL
interaction	NULL
(	NULL
Hsu	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
,	NULL
where	NULL
it	NULL
is	NULL
thought	NULL
to	NULL
mediate	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

Several	NULL
groups	NULL
have	NULL
reported	NULL
that	NULL
NP-	NULL
«	NULL
B	NULL
induction	NULL
can	NULL
confer	NULL
antiapoptotic	NULL
properties	NULL
on	NULL
the	NULL
cell	NULL
(	NULL
Beg	NULL
and	NULL
Baltimore	NULL
1996	NULL
;	NULL
Van	NULL
Antwerp	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Wang	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
a	NULL
dominant-negative	NULL
mutant	NULL
of	NULL
TRAF2	NULL
,	NULL
which	NULL
blocks	NULL
NF-KB	NULL
induction	NULL
by	NULL
TNFR1	NULL
,	NULL
potentiated	NULL
TNFR1-mediated	NULL
death	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
inhibition	NULL
of	NULL
TRAF2-induced	NULL
signaling	NULL
,	NULL
either	NULL
by	NULL
expression	NULL
of	NULL
a	NULL
dominant-negative	NULL
TRAF2	NULL
or	NULL
by	NULL
the	NULL
CD30-induced	NULL
degradation	NULL
of	NULL
TRAF2	NULL
,	NULL
can	NULL
sensitize	NULL
cells	NULL
to	NULL
TNFR1-mediated	NULL
death	NULL
.	NULL

Consistent	NULL
with	NULL
this	NULL
hypothesis	NULL
,	NULL
CD30	NULL
signal	NULL
transduction	NULL
and	NULL
concomitant	NULL
TRAF2	NULL
degradation	NULL
Degradation	NULL
of	NULL
TRAF2	NULL
by	NULL
CD30	NULL
abrogated	NULL
the	NULL
ability	NULL
of	NULL
TNF-a	NULL
to	NULL
induce	NULL
NF-KB	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

A	NULL
further	NULL
prediction	NULL
of	NULL
this	NULL
model	NULL
is	NULL
that	NULL
the	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
protease	NULL
inhibitors	NULL
that	NULL
can	NULL
block	NULL
TRAF2	NULL
degradation	NULL
might	NULL
confer	NULL
protection	NULL
to	NULL
death	NULL
induced	NULL
by	NULL
TNFR1	NULL
plus	NULL
CD30	NULL
signal	NULL
transduction	NULL
.	NULL

Preliminary	NULL
studies	NULL
suggest	NULL
that	NULL
this	NULL
is	NULL
the	NULL
case	NULL
(	NULL
C.S	NULL
.	NULL

Duckett	NULL
and	NULL
C.B	NULL
.	NULL

Thompson	NULL
,	NULL
unpubl	NULL
.	NULL
)	NULL

.	NULL

The	NULL
compounds	NULL
that	NULL
inhibit	NULL
TRAF2	NULL
degradation	NULL
,	NULL
however	NULL
,	NULL
also	NULL
cross-react	NULL
with	NULL
the	NULL
ubiquitin-proteasome	NULL
pathway	NULL
and	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
block	NULL
NF-	NULL
«	NULL
B	NULL
induction	NULL
by	NULL
TNF-a	NULL
,	NULL
and	NULL
the	NULL
combined	NULL
treatment	NULL
of	NULL
TNF-	NULL
«	NULL
plus	NULL
protease	NULL
inhibitors	NULL
was	NULL
found	NULL
to	NULL
be	NULL
toxic	NULL
to	NULL
the	NULL
untransfected	NULL
and	NULL
control	NULL
transfected	NULL
populations	NULL
of	NULL
cells	NULL
(	NULL
C.S	NULL
.	NULL

Duckett	NULL
and	NULL
C.B	NULL
.	NULL

Thompson	NULL
,	NULL
unpubl	NULL
.	NULL
)	NULL

.	NULL

These	NULL
studies	NULL
describe	NULL
a	NULL
mechanism	NULL
by	NULL
which	NULL
members	NULL
of	NULL
the	NULL
tum	NULL
or	NULL
necrosis	NULL
receptor	NULL
superfamily	NULL
may	NULL
cooperate	NULL
to	NULL
modulate	NULL
cell	NULL
survival	NULL
.	NULL

The	NULL
recruitment	NULL
of	NULL
TRAF2	NULL
to	NULL
the	NULL
cytoplasmic	NULL
tails	NULL
of	NULL
CD30	NULL
or	NULL
to	NULL
TNFR2	NULL
is	NULL
followed	NULL
by	NULL
its	NULL
degradation	NULL
.	NULL

There	NULL
are	NULL
at	NULL
least	NULL
two	NULL
consequences	NULL
of	NULL
this	NULL
event	NULL
.	NULL

First	NULL
,	NULL
the	NULL
removal	NULL
of	NULL
TRAF2	NULL
would	NULL
be	NULL
predicted	NULL
to	NULL
limit	NULL
the	NULL
duration	NULL
of	NULL
the	NULL
receptor-induced	NULL
signal	NULL
,	NULL
thus	NULL
ensuring	NULL
that	NULL
the	NULL
signal	NULL
is	NULL
self	NULL
regu-lating	NULL
.	NULL

Second	NULL
,	NULL
several	NULL
TNFR2Z-associated	NULL
proteins	NULL
,	NULL
such	NULL
as	NULL
TRAF2	NULL
and	NULL
the	NULL
c-IAPs	NULL
,	NULL
have	NULL
been	NULL
found	NULL
to	NULL
possess	NULL
antiapoptotic	NULL
properties	NULL
(	NULL
Liston	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Liu	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Uren	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
,	NULL
and	NULL
because	NULL
TRAFZ-associated	NULL
proteins	NULL
were	NULL
also	NULL
found	NULL
to	NULL
be	NULL
degraded	NULL
by	NULL
CD30	NULL
,	NULL
elimination	NULL
of	NULL
these	NULL
factors	NULL
might	NULL
be	NULL
predicted	NULL
to	NULL
sensitize	NULL
the	NULL
cell	NULL
to	NULL
additional	NULL
signals	NULL
such	NULL
as	NULL
those	NULL
mediated	NULL
by	NULL
TNFR1	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
)	NULL
.	NULL

The	NULL
observation	NULL
that	NULL
CD30	NULL
and	NULL
TNFR2	NULL
signaling	NULL
can	NULL
sensitize	NULL
cells	NULL
to	NULL
death	NULL
in	NULL
the	NULL
context	NULL
of	NULL
TNFR1	NULL
signals	NULL
might	NULL
also	NULL
explain	NULL
how	NULL
signaling	NULL
through	NULL
CD30	NULL
or	NULL
through	NULL
TNFR2	NULL
can	NULL
induce	NULL
disparate	NULL
effects	NULL
ranging	NULL
from	NULL
cellular	NULL
proliferation	NULL
to	NULL
apoptosis	NULL
(	NULL
Smith	NULL
et	NULL
al	NULL
.	NULL

1993	NULL
;	NULL
Stein	NULL
et	NULL
al	NULL
.	NULL

1985a	NULL
,	NULL
b	NULL
)	NULL
.	NULL

The	NULL
removal	NULL
of	NULL
TRAF2	NULL
by	NULL
degradation	NULL
might	NULL
therefore	NULL
be	NULL
expected	NULL
to	NULL
interfere	NULL
with	NULL
the	NULL
induction	NULL
by	NULL
TNFR1	NULL
of	NULL
antiapoptotic	NULL
signals	NULL
,	NULL
resulting	NULL
in	NULL
a	NULL
shift	NULL
to	NULL
the	NULL
remaining	NULL
TRADD-FADD-caspase	NULL
pathway	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
)	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
proteolytic	NULL
degradation	NULL
of	NULL
TRAF2	NULL
following	NULL
recruitment	NULL
to	NULL
CD30	NULL
and	NULL
TNFR2	NULL
will	NULL
result	NULL
in	NULL
the	NULL
termination	NULL
of	NULL
signal	NULL
transduction	NULL
through	NULL
these	NULL
receptors	NULL
.	NULL

Following	NULL
decay	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
kB-mediated	NULL
survival	NULL
signal	NULL
,	NULL
cells	NULL
will	NULL
be	NULL
subsequently	NULL
more	NULL
susceptible	NULL
to	NULL
dying	NULL
if	NULL
activated	NULL
by	NULL
death	NULL
domain-containing	NULL
receptors	NULL
such	NULL
as	NULL
TNFR1	NULL
,	NULL
unless	NULL
TRAF2	NULL
and	NULL
its	NULL
coassociated	NULL
signaling	NULL
molecules	NULL
can	NULL
be	NULL
regenerated	NULL
during	NULL
this	NULL
interval	NULL
.	NULL

Factors	NULL
that	NULL
increase	NULL
the	NULL
expression	NULL
of	NULL
these	NULL
proteins	NULL
are	NULL
,	NULL
therefore	NULL
,	NULL
likely	NULL
to	NULL
help	NULL
maintain	NULL
the	NULL
duration	NULL
of	NULL
survival	NULL
signaling	NULL
through	NULL
CD30	NULL
and	NULL
TNFR2	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
rate	NULL
of	NULL
receptor-mediated	NULL
TRAF2	NULL
consumption	NULL
and	NULL
TRAF2	NULL
translation	NULL
are	NULL
likely	NULL
to	NULL
play	NULL
a	NULL
dynamic	NULL
role	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
cell	NULL
survival	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Plasm	NULL
ids	NULL
The	NULL
chimeric	NULL
CD28-CD30	NULL
vectors	NULL
,	NULL
the	NULL
Atail	NULL
control	NULL
plasmid	NULL
,	NULL
and	NULL
the	NULL
expression	NULL
vectors	NULL
encoding	NULL
TRAF1l	NULL
,	NULL
TRAF2	NULL
,	NULL
and	NULL
GENES	NULL
&	NULL
DEVELOPMENT	NULL
2817	NULL
Duckett	NULL
and	NULL
Thompson	NULL
CD30	NULL
TNFRA1	NULL
TNFR2	NULL
TRADD	NULL
~a	NULL
@	NULL
..	NULL
/	NULL
_Fuice	NULL
I	NULL
TRaF2	NULL
|_	NULL
TRAF2	NULL
(	NULL
Casp	NULL
8	NULL
)	NULL
i	NULL
DEGRADATION	NULL
1	NULL
flute	NULL
|	NULL
``	NULL
J	NULL
4	NULL
NF-	NULL
«	NULL
B	NULL
|	NULL
APOPTOSIS	NULL
SURVIVAL	NULL
activation	NULL
Figure	NULL
9	NULL
.	NULL

Model	NULL
:	NULL
Control	NULL
of	NULL
TRAF2	NULL
levels	NULL
may	NULL
modulate	NULL
the	NULL
sensitivity	NULL
of	NULL
cells	NULL
to	NULL
TNFR1	NULL
signals	NULL
(	NULL
see	NULL
text	NULL
for	NULL
details	NULL
)	NULL
.	NULL

TRAF3	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
Duckett	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

The	NULL
ATraf	NULL
vector	NULL
encodes	NULL
the	NULL
CD28	NULL
extracellular	NULL
domain	NULL
fused	NULL
to	NULL
residues	NULL
410-531	NULL
of	NULL
CD30	NULL
,	NULL
a	NULL
deletion	NULL
that	NULL
previously	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
abrogate	NULL
TRAF	NULL
binding	NULL
(	NULL
Gedrich	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Duckett	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

The	NULL
CD28-TNFR2	NULL
chimera	NULL
was	NULL
constructed	NULL
by	NULL
PCR	NULL
amplification	NULL
of	NULL
the	NULL
TNFR2	NULL
cytoplasmic	NULL
tail	NULL
from	NULL
a	NULL
human	NULL
T-cell	NULL
cDNA	NULL
library	NULL
with	NULL
the	NULL
following	NULL
primers	NULL
:	NULL
S'-ATACTCGAGACAGGTGAAAAAGAAGCCCTTGTGCC-3	NULL
'	NULL
and	NULL
S'-AATTCTAGACCACCTTGGCTACGACACAGCC-CAC-3	NULL
'	NULL
.	NULL

The	NULL
PCR	NULL
product	NULL
was	NULL
subcloned	NULL
in-frame	NULL
into	NULL
the	NULL
modified	NULL
CD28	NULL
expression	NULL
vector	NULL
described	NULL
previously	NULL
(	NULL
Duckett	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

The	NULL
GFP	NULL
expression	NULL
vector	NULL
was	NULL
obtained	NULL
from	NULL
Clon-tech	NULL
laboratories	NULL
.	NULL

The	NULL
Myc	NULL
epitope-tagged	NULL
human	NULL
TRAPF4/	NULL
CART1	NULL
expression	NULL
vector	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
C.	NULL
Rudin	NULL
and	NULL
J	NULL
.	NULL

Van	NULL
Dongen	NULL
(	NULL
both	NULL
at	NULL
University	NULL
of	NULL
Chicago	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

The	NULL
murine	NULL
TRAFS	NULL
vector	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
R.	NULL
Arch	NULL
(	NULL
University	NULL
of	NULL
Chicago	NULL
,	NULL
IL	NULL
)	NULL
;	NULL
the	NULL
amino	NULL
terminus	NULL
was	NULL
modified	NULL
to	NULL
incorporate	NULL
the	NULL
Myc	NULL
epitope	NULL
tag	NULL
(	NULL
Duckett	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
prior	NULL
to	NULL
subcloning	NULL
into	NULL
the	NULL
peDNA3	NULL
mammalian	NULL
expression	NULL
vector	NULL
(	NULL
Invitrogen	NULL
)	NULL
.	NULL

Human	NULL
TRAF6	NULL
was	NULL
obtained	NULL
by	NULL
PCR	NULL
amplification	NULL
from	NULL
a	NULL
human	NULL
T-cell	NULL
cDNA	NULL
library	NULL
followed	NULL
by	NULL
subcloning	NULL
into	NULL
the	NULL
pFLAG-CMV-2	NULL
expression	NULL
vector	NULL
(	NULL
Kodak	NULL
)	NULL
.	NULL

Cells	NULL
and	NULL
transfections	NULL
Human	NULL
embryonic	NULL
kidney	NULL
293	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
Dul-becco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
(	NULL
DMEM	NULL
)	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
,	NULL
2	NULL
mM	NULL
glutamine	NULL
,	NULL
100	NULL
U/ml	NULL
of	NULL
penicillin	NULL
and	NULL
100	NULL
ug/ml	NULL
of	NULL
streptomycin	NULL
,	NULL
and	NULL
grown	NULL
at	NULL
37°C	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
.	NULL

Six-well	NULL
plates	NULL
were	NULL
seeded	NULL
with	NULL
2	NULL
x	NULL
10°	NULL
cells	NULL
per	NULL
well	NULL
in	NULL
2	NULL
ml	NULL
of	NULL
me-dium	NULL
.	NULL

The	NULL
medium	NULL
was	NULL
replaced	NULL
the	NULL
following	NULL
day	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
the	NULL
calcium	NULL
phosphate	NULL
procedure	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
Duckett	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

Viability	NULL
assays	NULL
Cells	NULL
were	NULL
cotransfected	NULL
with	NULL
100	NULL
ng	NULL
of	NULL
GFP	NULL
plasmid	NULL
and	NULL
1	NULL
ug	NULL
of	NULL
CD28	NULL
chimeric	NULL
plasmid	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
text	NULL
.	NULL

Unless	NULL
2818	NULL
GENES	NULL
&	NULL
DEVELOPMENT	NULL
stated	NULL
otherwise	NULL
,	NULL
the	NULL
medium	NULL
was	NULL
removed	NULL
12	NULL
hr	NULL
post-transfec-tion	NULL
and	NULL
replaced	NULL
either	NULL
with	NULL
fresh	NULL
medium	NULL
containing	NULL
human	NULL
recombinant	NULL
TNF-	NULL
«	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
at	NULL
200	NULL
U/ml	NULL
or	NULL
with	NULL
medium	NULL
alone	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
maintained	NULL
for	NULL
a	NULL
further	NULL
18	NULL
to	NULL
24	NULL
hr	NULL
as	NULL
indicated	NULL
,	NULL
before	NULL
harvest	NULL
.	NULL

Medium	NULL
from	NULL
transfected	NULL
cells	NULL
was	NULL
collected	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
once	NULL
with	NULL
phosphate	NULL
buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
supplemented	NULL
with	NULL
1	NULL
mM	NULL
ethylenedi-aminetetraacetic	NULL
acid	NULL
(	NULL
EDTA	NULL
)	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
detached	NULL
from	NULL
the	NULL
plate	NULL
in	NULL
the	NULL
same	NULL
buffer	NULL
.	NULL

Cells	NULL
,	NULL
washes	NULL
,	NULL
and	NULL
medium	NULL
were	NULL
pooled	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
pelleted	NULL
by	NULL
centrifugation	NULL
at	NULL
1500	NULL
rpm	NULL
at	NULL
4°C	NULL
.	NULL

Pellets	NULL
were	NULL
washed	NULL
once	NULL
in	NULL
PBS/EDTA	NULL
and	NULL
fixed	NULL
in	NULL
PBS	NULL
containing	NULL
1.25	NULL
%	NULL
glutaraldehyde	NULL
(	NULL
1	NULL
ml	NULL
)	NULL
Fixed	NULL
cells	NULL
were	NULL
washed	NULL
once	NULL
with	NULL
PBS	NULL
,	NULL
resuspended	NULL
in	NULL
1	NULL
ml	NULL
PBS	NULL
containing	NULL
4',6'-diamidino-2-phenylindole	NULL
(	NULL
DAPD	NULL
)	NULL
at	NULL
20	NULL
ng/ml	NULL
,	NULL
and	NULL
incubated	NULL
for	NULL
10	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Stained	NULL
cells	NULL
were	NULL
washed	NULL
once	NULL
in	NULL
PBS	NULL
and	NULL
resuspended	NULL
in	NULL
1	NULL
ml	NULL
PBS	NULL
.	NULL

Aliquots	NULL
(	NULL
typically	NULL
50	NULL
ul	NULL
)	NULL
were	NULL
spun	NULL
onto	NULL
microscope	NULL
slides	NULL
with	NULL
a	NULL
Cy-topro	NULL
cytocentrifuge	NULL
(	NULL
Wescor	NULL
)	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
examined	NULL
by	NULL
fluorescence	NULL
microscopy	NULL
by	NULL
use	NULL
of	NULL
a	NULL
Leitz	NULL
DM-RB	NULL
microscope	NULL
.	NULL

Analysis	NULL
of	NULL
TRAF	NULL
protein	NULL
levels	NULL
Cells	NULL
were	NULL
cotransfected	NULL
with	NULL
100	NULL
ng	NULL
of	NULL
the	NULL
indicated	NULL
CD28	NULL
chimeric	NULL
vector	NULL
and	NULL
1	NULL
ug	NULL
of	NULL
TRAF	NULL
expression	NULL
vector	NULL
.	NULL

Lysates	NULL
were	NULL
prepared	NULL
12-48	NULL
hr	NULL
after	NULL
transfection	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
figure	NULL
legends	NULL
,	NULL
as	NULL
follows	NULL
:	NULL
Cells	NULL
were	NULL
washed	NULL
once	NULL
in	NULL
PBS	NULL
and	NULL
lysed	NULL
in	NULL
0.5	NULL
m1	NULL
of	NULL
lysis	NULL
buffer	NULL
[	NULL
25	NULL
mm	NULL
HEPES	NULL
at	NULL
pH	NULL
7.9	NULL
,	NULL
100	NULL
mM	NULL
NaCl	NULL
,	NULL
1	NULL
mm	NULL
EDTA	NULL
,	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
1	NULL
mm	NULL
di-thiothreitol	NULL
,	NULL
0.1	NULL
mM	NULL
phenylmethanesulfonyl	NULL
fluoride	NULL
,	NULL
and	NULL
a	NULL
cocktail	NULL
of	NULL
protease	NULL
inhibitors	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
]	NULL
.	NULL

Protein	NULL
levels	NULL
were	NULL
standardized	NULL
with	NULL
the	NULL
Bradford	NULL
reagent	NULL
(	NULL
Bio-Rad	NULL
)	NULL
.	NULL

Samples	NULL
were	NULL
electrophoresed	NULL
on	NULL
9.5	NULL
%	NULL
SDS-polyacrylamide	NULL
gels	NULL
and	NULL
immunoblotted	NULL
with	NULL
commercial	NULL
rabbit	NULL
polyclonal	NULL
antibodies	NULL
to	NULL
human	NULL
TRAF1	NULL
,	NULL
TRAF2	NULL
,	NULL
or	NULL
TRAF3	NULL
(	NULL
Santa	NULL
Cruz	NULL
Bio-technologies	NULL
)	NULL
or	NULL
with	NULL
murine	NULL
monoclonal	NULL
antibodies	NULL
to	NULL
the	NULL
Myc	NULL
epitope	NULL
(	NULL
Pharmingen	NULL
;	NULL
clone	NULL
9E10	NULL
)	NULL
or	NULL
FLAG	NULL
(	NULL
Kodak	NULL
;	NULL
M2	NULL
)	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
text	NULL
.	NULL

Blots	NULL
were	NULL
subsequently	NULL
probed	NULL
with	NULL
horseradish	NULL
peroxidase-conjugated	NULL
anti-rabbit	NULL
or	NULL
anti-mouse	NULL
monoclonal	NULL
antibodies	NULL
(	NULL
Amersham	NULL
)	NULL
as	NULL
required	NULL
and	NULL
developed	NULL
with	NULL
an	NULL
enhanced	NULL
chemiluminescence	NULL
detection	NULL
system	NULL
(	NULL
Am-ersham	NULL
)	NULL
.	NULL

RNA	NULL
extraction	NULL
and	NULL
Northern	NULL
blot	NULL
analysis	NULL
Total	NULL
cellular	NULL
RNA	NULL
was	NULL
isolated	NULL
with	NULL
the	NULL
TRIzol	NULL
protocol	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
.	NULL

RN	NULL
A	NULL
quantitation	NULL
,	NULL
electrophoresis	NULL
,	NULL
and	NULL
transfer	NULL
to	NULL
nitrocellulose	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
Yang	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
,	NULL
and	NULL
blots	NULL
were	NULL
probed	NULL
with	NULL
a	NULL
nick-translated	NULL
*°P-labeled	NULL
DNA	NULL
fragment	NULL
encompassing	NULL
residues	NULL
87-501	NULL
of	NULL
human	NULL
TRAF2	NULL
.	NULL

Reporter	NULL
gene	NULL
analysis	NULL
Six-well	NULL
plates	NULL
were	NULL
seeded	NULL
with	NULL
293	NULL
cells	NULL
at	NULL
a	NULL
density	NULL
of	NULL
5	NULL
x	NULL
10°	NULL
cells	NULL
per	NULL
well	NULL
in	NULL
2	NULL
ml	NULL
of	NULL
medium	NULL
,	NULL
and	NULL
triplicate	NULL
wells	NULL
were	NULL
transfected	NULL
with	NULL
50	NULL
ng	NULL
each	NULL
of	NULL
a	NULL
«	NULL
B-responsive	NULL
luciferase	NULL
reporter	NULL
plasmid	NULL
containing	NULL
two	NULL
canonical	NULL
kB	NULL
sites	NULL
(	NULL
Klug	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
)	NULL
and	NULL
a	NULL
B-galactosidase	NULL
transfection	NULL
efficiency	NULL
control	NULL
plasmid	NULL
,	NULL
together	NULL
with	NULL
100	NULL
ng	NULL
of	NULL
either	NULL
the	NULL
CD28-CD30	NULL
or	NULL
the	NULL
Atail	NULL
control	NULL
plasmid	NULL
,	NULL
as	NULL
indicated	NULL
.	NULL

Transfectants	NULL
were	NULL
maintained	NULL
for	NULL
48	NULL
hr	NULL
and	NULL
stimulated	NULL
where	NULL
indicated	NULL
with	NULL
recombinant	NULL
human	NULL
TNF-	NULL
«	NULL
@	NULL
00	NULL
U/ml	NULL
;	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
or	NULL
a	NULL
medium	NULL
control	NULL
for	NULL
10	NULL
hr	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
and	NULL
luciferase	NULL
reporter	NULL
gene	NULL
activity	NULL
assayed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
Duckett	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
R.	NULL
Arch	NULL
,	NULL
R.	NULL
Gedrich	NULL
,	NULL
M.	NULL
Gilfillan	NULL
,	NULL
A.	NULL
Minn	NULL
,	NULL
C.	NULL
Rudin	NULL
,	NULL
and	NULL
members	NULL
of	NULL
the	NULL
Thompson	NULL
lab	NULL
for	NULL
thoughtful	NULL
discussions	NULL
and	NULL
critical	NULL
review	NULL
of	NULL
the	NULL
manuscript	NULL
;	NULL
R.	NULL
Arch	NULL
,	NULL
C.	NULL
Rudin	NULL
,	NULL
and	NULL
J	NULL
.	NULL

Van	NULL
Dongen	NULL
for	NULL
providing	NULL
TRAF4	NULL
and	NULL
TRAFS5	NULL
cDN	NULL
As	NULL
;	NULL
H.	NULL
Singh	NULL
for	NULL
providing	NULL
luciferase	NULL
plasmids	NULL
;	NULL
and	NULL
T.	NULL
Lindsten	NULL
for	NULL
assistance	NULL
with	NULL
Northern	NULL
blots	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
research	NULL
grant	NULL
PO1	NULL
DK49799	NULL
(	NULL
to	NULL
C.B.T	NULL
.	NULL
)	NULL

from	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
.	NULL

C.S.D	NULL
.	NULL

is	NULL
a	NULL
Special	NULL
Fellow	NULL
of	NULL
the	NULL
Leukemia	NULL
Society	NULL
of	NULL
America	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
USC	NULL
section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

References	NULL
Aizawa	NULL
,	NULL
S.	NULL
,	NULL
H.	NULL
Nakano	NULL
,	NULL
T.	NULL
Ishida	NULL
,	NULL
R.	NULL
Horie	NULL
,	NULL
M.	NULL
Nagai	NULL
,	NULL
K.	NULL
Ito	NULL
,	NULL
H.	NULL
Yagita	NULL
,	NULL
K.	NULL
Okumura	NULL
,	NULL
J.	NULL
Inoue	NULL
,	NULL
and	NULL
T.	NULL
Watanabe	NULL
.	NULL

1997	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
receptor-associated	NULL
factor	NULL
(	NULL
TRAF	NULL
)	NULL
5	NULL
and	NULL
TRAF2	NULL
are	NULL
involved	NULL
in	NULL
CD30-mediated	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

J	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

2721	NULL
:	NULL
2042-2045	NULL
.	NULL

Allison	NULL
,	NULL
J.	NULL
and	NULL
M.F	NULL
.	NULL

Krummel	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
yin	NULL
and	NULL
yan	NULL
of	NULL
T	NULL
cell	NULL
costimulation	NULL
.	NULL

Science	NULL
270:932-933	NULL
.	NULL

Amakawa	NULL
,	NULL
R.	NULL
,	NULL
A.	NULL
Hakem	NULL
,	NULL
TM	NULL
.	NULL

Kundig	NULL
,	NULL
T.	NULL
Matsuyama	NULL
,	NULL
JJ.L	NULL
.	NULL

Simard	NULL
,	NULL
E.	NULL
Timms	NULL
,	NULL
A.	NULL
Wakeham	NULL
,	NULL
H.-W.	NULL
Mittruecker	NULL
,	NULL
H.	NULL
Griesser	NULL
,	NULL
H.	NULL
Takimoto	NULL
,	NULL
R.	NULL
Schmits	NULL
,	NULL
A.	NULL
Shahinian	NULL
,	NULL
P.S	NULL
.	NULL

Ohashi	NULL
,	NULL
J.M	NULL
.	NULL

Penninger	NULL
,	NULL
and	NULL
T.W	NULL
.	NULL

Mak	NULL
.	NULL

1996	NULL
.	NULL

Impaired	NULL
negative	NULL
selection	NULL
of	NULL
T	NULL
cells	NULL
in	NULL
Hodgkin	NULL
's	NULL
disease	NULL
antigen	NULL
CD30-defi-cient	NULL
mice	NULL
.	NULL

Cell	NULL
84	NULL
:	NULL
551-562	NULL
.	NULL

Ansieau	NULL
,	NULL
S.	NULL
,	NULL
I.	NULL
Scheffrahn	NULL
,	NULL
G.	NULL
Mosialos	NULL
,	NULL
H.	NULL
Brand	NULL
,	NULL
J.	NULL
Duyster	NULL
,	NULL
K.	NULL
Kaye	NULL
,	NULL
J.	NULL
Harada	NULL
,	NULL
B.	NULL
Dougall	NULL
,	NULL
G.	NULL
Hiibinger	NULL
,	NULL
E.	NULL
Kieff	NULL
,	NULL
F.	NULL
Her-mann	NULL
,	NULL
A.	NULL
Leutz	NULL
,	NULL
and	NULL
H.-J	NULL
.	NULL

Gruss	NULL
.	NULL

1996	NULL
.	NULL

Tum	NULL
or	NULL
necrosis	NULL
factor	NULL
receptor-associated	NULL
factor	NULL
(	NULL
TRAF	NULL
)	NULL
1	NULL
,	NULL
TRAF-2	NULL
,	NULL
and	NULL
TRAF-3	NULL
interact	NULL
in	NULL
vivo	NULL
with	NULL
the	NULL
CD30	NULL
cytoplasmic	NULL
domain	NULL
;	NULL
TRAF-2	NULL
mediates	NULL
CD30-induced	NULL
nuclear	NULL
factor	NULL
kappa	NULL
B	NULL
activation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

931	NULL
14053-14058	NULL
.	NULL

Armitage	NULL
,	NULL
R.J.	NULL
1994	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
superfamily	NULL
members	NULL
and	NULL
their	NULL
ligands	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

61407-413	NULL
.	NULL

Baker	NULL
,	NULL
S.J	NULL
.	NULL

and	NULL
E.P	NULL
.	NULL

Reddy	NULL
.	NULL

1996	NULL
.	NULL

Transducers	NULL
of	NULL
life	NULL
and	NULL
death	NULL
:	NULL
TNF	NULL
receptor	NULL
superfamily	NULL
and	NULL
associated	NULL
proteins	NULL
.	NULL

Onco-gene	NULL
1211-9	NULL
.	NULL

Beg	NULL
,	NULL
A.A.	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1996	NULL
.	NULL

An	NULL
essential	NULL
role	NULL
for	NULL
NF-KB	NULL
in	NULL
preventing	NULL
TNF-	NULL
«	NULL
-induced	NULL
cell	NULL
death	NULL
.	NULL

Science	NULL
274	NULL
:	NULL
782-784	NULL
.	NULL

Beyaert	NULL
,	NULL
R.	NULL
and	NULL
W.	NULL
Fiers	NULL
.	NULL

1994	NULL
.	NULL

Molecular	NULL
mechanism	NULL
s	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor-induced	NULL
cytotoxicity	NULL
.	NULL

What	NULL
we	NULL
do	NULL
understand	NULL
and	NULL
what	NULL
we	NULL
do	NULL
not	NULL
.	NULL

FEBS	NULL
Lett	NULL
.	NULL

340	NULL
:	NULL
9-16	NULL
.	NULL

Biswas	NULL
,	NULL
P.	NULL
,	NULL
C.A	NULL
.	NULL

Smith	NULL
,	NULL
D.	NULL
Goletti	NULL
,	NULL
E.C	NULL
.	NULL

Hardy	NULL
,	NULL
R.W	NULL
.	NULL

Jackson	NULL
,	NULL
and	NULL
A.S.	NULL
Fauci	NULL
.	NULL

1995	NULL
.	NULL

Cross-linking	NULL
of	NULL
CD30	NULL
induces	NULL
HIV	NULL
expression	NULL
in	NULL
chronically	NULL
infected	NULL
T	NULL
cells	NULL
.	NULL

Immunity	NULL
21	NULL
587-596	NULL
.	NULL

Bump	NULL
,	NULL
N.J.	NULL
,	NULL
M.	NULL
Hackett	NULL
,	NULL
M.	NULL
Hugunin	NULL
,	NULL
S.	NULL
Seshagiri	NULL
,	NULL
K.	NULL
Brady	NULL
,	NULL
P.	NULL
Chen	NULL
,	NULL
C.	NULL
Ferenz	NULL
,	NULL
S.	NULL
Franklin	NULL
,	NULL
T.	NULL
Ghayur	NULL
,	NULL
P.	NULL
Li	NULL
,	NULL
P.	NULL
Licari	NULL
,	NULL
J.	NULL
Mankovich	NULL
,	NULL
L.	NULL
Shi	NULL
,	NULL
A.H.	NULL
Greenberg	NULL
,	NULL
LK	NULL
.	NULL

Miller	NULL
,	NULL
and	NULL
W.W.	NULL
Wong	NULL
.	NULL

1995	NULL
.	NULL

Inhibition	NULL
of	NULL
ICE	NULL
family	NULL
proteases	NULL
by	NULL
baculovirus	NULL
antiapoptotic	NULL
protein	NULL
p35	NULL
.	NULL

Science	NULL
269	NULL
:	NULL
1885-1888	NULL
.	NULL

Cao	NULL
,	NULL
Z.	NULL
,	NULL
J.	NULL
Xiong	NULL
,	NULL
M.	NULL
Takeuchi	NULL
,	NULL
T.	NULL
Kurama	NULL
,	NULL
and	NULL
D.V	NULL
.	NULL

Goeddel	NULL
.	NULL

1996	NULL
.	NULL

TRAF6	NULL
is	NULL
a	NULL
signal	NULL
transducer	NULL
for	NULL
interleukin-1	NULL
.	NULL

Nature	NULL
383	NULL
:	NULL
443-446	NULL
.	NULL

Chen	NULL
,	NULL
Z.	NULL
,	NULL
J.	NULL
Hagler	NULL
,	NULL
V.J	NULL
.	NULL

Palom	NULL
bella	NULL
,	NULL
F.	NULL
Melandri	NULL
,	NULL
D.	NULL
Scherer	NULL
,	NULL
D.	NULL
Ballard	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1995	NULL
.	NULL

Signal-induced	NULL
site-specific	NULL
phosphorylation	NULL
targets	NULL
IxBa	NULL
«	NULL
to	NULL
the	NULL
ubiquitin-proteasome	NULL
pathway	NULL
.	NULL

Genes	NULL
&	NULL
Dev	NULL
.	NULL

9	NULL
:	NULL
1586-1597	NULL
.	NULL

Chen	NULL
,	NULL
Z.	NULL
,	NULL
L.	NULL
Parent	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1996	NULL
.	NULL

Site-specific	NULL
phosphorylation	NULL
of	NULL
IkB	NULL
«	NULL
by	NULL
a	NULL
novel	NULL
ubiquitination-dependent	NULL
Degradation	NULL
of	NULL
TRAF2	NULL
by	NULL
CD30	NULL
protein	NULL
kinase	NULL
activity	NULL
.	NULL

Cell	NULL
84	NULL
:	NULL
853-862	NULL
.	NULL

Cheng	NULL
,	NULL
G.	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1996	NULL
.	NULL

TANK	NULL
,	NULL
a	NULL
co-inducer	NULL
with	NULL
TRAF2	NULL
of	NULL
TNF-	NULL
and	NULL
CD4O0L-mediated	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

Genes	NULL
&	NULL
Dev	NULL
.	NULL

10:963-973	NULL
.	NULL

Chinnaiyan	NULL
,	NULL
A.M.	NULL
,	NULL
K.	NULL
O'Rourke	NULL
,	NULL
M.	NULL
Tewari	NULL
,	NULL
and	NULL
V.M	NULL
.	NULL

Dixit	NULL
.	NULL

1995	NULL
.	NULL

FADD	NULL
,	NULL
a	NULL
novel	NULL
death	NULL
domain-containing	NULL
protein	NULL
,	NULL
interacts	NULL
with	NULL
the	NULL
death	NULL
domain	NULL
of	NULL
Fas	NULL
and	NULL
initiates	NULL
apoptosis	NULL
.	NULL

Cell	NULL
81	NULL
:	NULL
505-512	NULL
.	NULL

Chinnaiyan	NULL
,	NULL
A.M.	NULL
,	NULL
K.	NULL
O'Rourke	NULL
,	NULL
G.-L.	NULL
Yu	NULL
,	NULL
R.H.	NULL
Lyons	NULL
,	NULL
M.	NULL
Garg	NULL
,	NULL
D.R	NULL
.	NULL

Duan	NULL
,	NULL
L.	NULL
Xing	NULL
,	NULL
R.	NULL
Gentz	NULL
,	NULL
J.	NULL
Ni	NULL
,	NULL
and	NULL
V.M	NULL
.	NULL

Dixit	NULL
.	NULL

1996	NULL
.	NULL

Signal	NULL
transduction	NULL
by	NULL
DR3	NULL
,	NULL
a	NULL
death	NULL
domain-containing	NULL
receptor	NULL
related	NULL
to	NULL
TNFR-1	NULL
and	NULL
CD95	NULL
.	NULL

Science	NULL
274	NULL
:	NULL
990-992	NULL
.	NULL

Choi	NULL
,	NULL
M.S	NULL
.	NULL

,	NULL
LH	NULL
.	NULL

Boise	NULL
,	NULL
A.R	NULL
.	NULL

Gottschalk	NULL
,	NULL
J.	NULL
Quintans	NULL
,	NULL
C.B	NULL
.	NULL

Thompson	NULL
,	NULL
and	NULL
G.G	NULL
.	NULL

Klaus	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
role	NULL
of	NULL
bel-x	NULL
,	NULL
,	NULL
in	NULL
CD40-mediated	NULL
rescue	NULL
from	NULL
anti-u-induced	NULL
apoptosis	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

251	NULL
1352-1357	NULL
.	NULL

Clem	NULL
,	NULL
R.J.	NULL
,	NULL
M.	NULL
Fechheimer	NULL
,	NULL
and	NULL
L.K	NULL
.	NULL

Miller	NULL
.	NULL

1991	NULL
.	NULL

Prevention	NULL
of	NULL
apoptosis	NULL
by	NULL
a	NULL
baculovirus	NULL
gene	NULL
during	NULL
infection	NULL
of	NULL
insect	NULL
cells	NULL
.	NULL

Science	NULL
254	NULL
:	NULL
1388-1390	NULL
.	NULL

Del	NULL
Prete	NULL
,	NULL
G.	NULL
,	NULL
M.	NULL
De	NULL
Carli	NULL
,	NULL
M.M	NULL
.	NULL

D'Elios	NULL
,	NULL
K.C	NULL
.	NULL

Daniel	NULL
,	NULL
F.	NULL
Alm	NULL
erigogna	NULL
,	NULL
M.	NULL
Alderson	NULL
,	NULL
C.A	NULL
.	NULL

Smith	NULL
,	NULL
E.	NULL
Thomas	NULL
,	NULL
and	NULL
S.	NULL
Romagnani	NULL
.	NULL

1995	NULL
.	NULL

CD30-mediated	NULL
signaling	NULL
promotes	NULL
the	NULL
development	NULL
of	NULL
human	NULL
T	NULL
helper	NULL
type	NULL
2-like	NULL
cells	NULL
.	NULL

L	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

182	NULL
:	NULL
1655-1661	NULL
.	NULL

DiDonato	NULL
,	NULL
JA	NULL
.	NULL

,	NULL
F.	NULL
Mercurio	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1995	NULL
.	NULL

Phophoryla-tion	NULL
of	NULL
IxBa	NULL
precedes	NULL
but	NULL
is	NULL
not	NULL
sufficient	NULL
for	NULL
its	NULL
dissociation	NULL
from	NULL
NF-kB	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:1302-1311	NULL
.	NULL

DiDonato	NULL
,	NULL
J.	NULL
,	NULL
F.	NULL
Mercurio	NULL
,	NULL
C.	NULL
Rosette	NULL
,	NULL
J.	NULL
Wu-Li	NULL
,	NULL
H.	NULL
Suyang	NULL
,	NULL
S.	NULL
Ghosh	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1996	NULL
.	NULL

Mapping	NULL
of	NULL
the	NULL
inducible	NULL
IxB	NULL
phosphorylation	NULL
sites	NULL
that	NULL
signal	NULL
its	NULL
ubiquitination	NULL
and	NULL
degradation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16	NULL
:	NULL
1295-1304	NULL
.	NULL

Duckett	NULL
,	NULL
C.S	NULL
.	NULL

,	NULL
V.E	NULL
.	NULL

Nava	NULL
,	NULL
RW	NULL
.	NULL

Gedrich	NULL
,	NULL
R.J.	NULL
Clem	NULL
,	NULL
J.L	NULL
.	NULL

Van	NULL
Dongen	NULL
,	NULL
M.C	NULL
.	NULL

Gilfillan	NULL
,	NULL
H.	NULL
Shiels	NULL
,	NULL
JLM	NULL
.	NULL

Hardwick	NULL
,	NULL
and	NULL
C.B	NULL
.	NULL

Thompson	NULL
.	NULL

1996	NULL
.	NULL

A	NULL
conserved	NULL
family	NULL
of	NULL
cellular	NULL
genes	NULL
related	NULL
to	NULL
the	NULL
baculovirus	NULL
fap	NULL
gene	NULL
and	NULL
encoding	NULL
apoptosis	NULL
inhibitors	NULL
.	NULL

EMBO	NULL
J	NULL
15	NULL
:	NULL
2685-2694	NULL
.	NULL

Duckett	NULL
,	NULL
C.S	NULL
.	NULL

,	NULL
RW	NULL
.	NULL

Gedrich	NULL
,	NULL
M.C	NULL
.	NULL

Gilfillan	NULL
,	NULL
and	NULL
C.B	NULL
.	NULL

Thompson	NULL
.	NULL

1997	NULL
.	NULL

Induction	NULL
of	NULL
nuclear	NULL
factor	NULL
kB	NULL
by	NULL
the	NULL
CD30	NULL
receptor	NULL
is	NULL
mediated	NULL
by	NULL
TRAFl	NULL
and	NULL
TRAF2	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

17	NULL
:	NULL
1535-1542	NULL
.	NULL

Diirkop	NULL
,	NULL
H.	NULL
,	NULL
U.	NULL
Latza	NULL
,	NULL
M.	NULL
Hummel	NULL
,	NULL
F.	NULL
Eitelbach	NULL
,	NULL
B	NULL
.	NULL

Seed	NULL
,	NULL
and	NULL
H.	NULL
Stein	NULL
.	NULL

1992	NULL
.	NULL

Molecular	NULL
cloning	NULL
and	NULL
expression	NULL
of	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
nerve	NULL
growth	NULL
factor	NULL
receptor	NULL
family	NULL
that	NULL
is	NULL
characteristic	NULL
for	NULL
Hodgkin	NULL
's	NULL
disease	NULL
.	NULL

Cell	NULL
68	NULL
:	NULL
421-427	NULL
.	NULL

Ellis	NULL
,	NULL
TM	NULL
.	NULL

,	NULL
P.E	NULL
.	NULL

Simms	NULL
,	NULL
D.J	NULL
.	NULL

Slivnick	NULL
,	NULL
H.-M.	NULL
Jick	NULL
,	NULL
and	NULL
R.	NULL
Fisher	NULL
.	NULL

1993	NULL
.	NULL

CD30	NULL
is	NULL
a	NULL
signal-transducing	NULL
molecule	NULL
that	NULL
defines	NULL
a	NULL
subset	NULL
of	NULL
human	NULL
activated	NULL
CD45RO*	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
Im	NULL
m	NULL
unol	NULL
.	NULL

151	NULL
:	NULL
2380-2389	NULL
.	NULL

Falini	NULL
,	NULL
B.	NULL
,	NULL
S.	NULL
Pileri	NULL
,	NULL
G.	NULL
Pizzolo	NULL
,	NULL
H.	NULL
Diirkop	NULL
,	NULL
L.	NULL
Flenghi	NULL
,	NULL
F.	NULL
Stirpe	NULL
,	NULL
M.F	NULL
.	NULL

Martelli	NULL
,	NULL
and	NULL
H.	NULL
Stein	NULL
.	NULL

1995	NULL
.	NULL

CD30	NULL
(	NULL
Ki-1	NULL
)	NULL
molecule	NULL
:	NULL
A	NULL
new	NULL
cytokine	NULL
receptor	NULL
of	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
superfamily	NULL
as	NULL
a	NULL
tool	NULL
for	NULL
diagnosis	NULL
and	NULL
immunotherapy	NULL
.	NULL

Blood	NULL
8511-14	NULL
.	NULL

Foy	NULL
,	NULL
T.M	NULL
.	NULL

,	NULL
A.	NULL
Aruffo	NULL
,	NULL
J.	NULL
Bajorath	NULL
,	NULL
JE	NULL
.	NULL

Buhlmann	NULL
,	NULL
and	NULL
R.J.	NULL
Noelle	NULL
.	NULL

1996	NULL
.	NULL

Immune	NULL
regulation	NULL
by	NULL
CD40	NULL
and	NULL
its	NULL
ligand	NULL
gp39	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

141	NULL
591-617	NULL
.	NULL

Gagliardini	NULL
,	NULL
V.	NULL
,	NULL
P.A	NULL
.	NULL

Fernandez	NULL
,	NULL
R.K.	NULL
Lee	NULL
,	NULL
H.C.	NULL
Drexler	NULL
,	NULL
R.J.	NULL
Ro-tello	NULL
,	NULL
M.C	NULL
.	NULL

Fishman	NULL
,	NULL
and	NULL
J.	NULL
Yuan	NULL
.	NULL

1994	NULL
.	NULL

Prevention	NULL
of	NULL
vertebrate	NULL
neuronal	NULL
death	NULL
by	NULL
the	NULL
crm	NULL
A	NULL
gene	NULL
.	NULL

Science	NULL
263:826-828	NULL
.	NULL

Gedrich	NULL
,	NULL
RW	NULL
.	NULL

,	NULL
M.C	NULL
.	NULL

Gilfillan	NULL
,	NULL
C.S	NULL
.	NULL

Duckett	NULL
,	NULL
J.L	NULL
.	NULL

Van	NULL
Dongen	NULL
,	NULL
and	NULL
C.B	NULL
.	NULL

Thompson	NULL
.	NULL

1996	NULL
.	NULL

CD30	NULL
contains	NULL
two	NULL
binding	NULL
sites	NULL
with	NULL
different	NULL
specificities	NULL
for	NULL
members	NULL
of	NULL
the	NULL
TRAF	NULL
family	NULL
of	NULL
signal	NULL
transducing	NULL
proteins	NULL
.	NULL

J	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:12852-12858	NULL
.	NULL

Grell	NULL
,	NULL
M.	NULL
,	NULL
E.	NULL
Douni	NULL
,	NULL
H.	NULL
Wajant	NULL
,	NULL
M.	NULL
Lohden	NULL
,	NULL
M.	NULL
Clauss	NULL
,	NULL
B.	NULL
Max	NULL
GENES	NULL
&	NULL
DEVELOPMENT	NULL
2819	NULL
Duckett	NULL
and	NULL
Thompson	NULL
einer	NULL
,	NULL
S.	NULL
Georgopoulos	NULL
,	NULL
W.	NULL
Lesslauer	NULL
,	NULL
G.	NULL
Kollias	NULL
,	NULL
K.	NULL
Pfizen-maier	NULL
,	NULL
and	NULL
P.	NULL
Scheurich	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
transmembrane	NULL
form	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
is	NULL
the	NULL
prime	NULL
activating	NULL
ligand	NULL
of	NULL
the	NULL
80	NULL
kDa	NULL
tum	NULL
or	NULL
necrosis	NULL
factor	NULL
receptor	NULL
.	NULL

Cell	NULL
83	NULL
:	NULL
793-802	NULL
.	NULL

Gruss	NULL
,	NULL
H.-J	NULL
.	NULL

and	NULL
S.K	NULL
.	NULL

Dower	NULL
.	NULL

1995	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
ligand	NULL
superfamily	NULL
:	NULL
Involvement	NULL
in	NULL
the	NULL
pathology	NULL
of	NULL
malignant	NULL
lymphomas	NULL
.	NULL

Blood	NULL
85	NULL
:	NULL
3378-3404	NULL
.	NULL

Hateboer	NULL
,	NULL
G.	NULL
,	NULL
R.M	NULL
.	NULL

Kerkhoven	NULL
,	NULL
A.	NULL
Shvarts	NULL
,	NULL
R.	NULL
Bernards	NULL
,	NULL
and	NULL
RL	NULL
.	NULL

Beijersbergen	NULL
.	NULL

1996	NULL
.	NULL

Degradation	NULL
of	NULL
E2F	NULL
by	NULL
the	NULL
ubiquitin-proteasome	NULL
pathway	NULL
:	NULL
Regulation	NULL
by	NULL
retinoblastoma	NULL
family	NULL
proteins	NULL
and	NULL
adenovirus	NULL
transforming	NULL
proteins	NULL
.	NULL

Genes	NULL
&	NULL
Dev	NULL
.	NULL

10	NULL
:	NULL
2960-2970	NULL
.	NULL

Henkel	NULL
,	NULL
T.	NULL
,	NULL
T.	NULL
Machleidt	NULL
,	NULL
I.	NULL
Alkalay	NULL
,	NULL
M.	NULL
Krdnke	NULL
,	NULL
Y.	NULL
Ben-Neriah	NULL
,	NULL
and	NULL
P.A	NULL
.	NULL

Bacuerle	NULL
.	NULL

1995	NULL
.	NULL

Rapid	NULL
proteolysis	NULL
of	NULL
IxB-	NULL
«	NULL
is	NULL
necessary	NULL
for	NULL
activation	NULL
of	NULL
transcription	NULL
factor	NULL
NF-kB	NULL
.	NULL

Nature	NULL
365	NULL
:	NULL
182-185	NULL
.	NULL

Hsu	NULL
,	NULL
H.	NULL
,	NULL
J.	NULL
Xiong	NULL
,	NULL
and	NULL
D.V	NULL
.	NULL

Goeddel	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
TNF	NULL
receptor	NULL
l-associated	NULL
protein	NULL
TRADD	NULL
signals	NULL
cell	NULL
death	NULL
and	NULL
NF-kB	NULL
activation	NULL
.	NULL

Cell	NULL
81:495-504	NULL
.	NULL

Hsu	NULL
,	NULL
H.	NULL
,	NULL
H.-B	NULL
.	NULL

Shu	NULL
,	NULL
M.-G.	NULL
Pan	NULL
,	NULL
and	NULL
D.V	NULL
.	NULL

Goeddel	NULL
.	NULL

1996	NULL
.	NULL

TRADD-TRAF2	NULL
and	NULL
TRADD-FADD	NULL
interactions	NULL
define	NULL
two	NULL
distinct	NULL
TNF	NULL
receptor	NULL
1	NULL
signal	NULL
transduction	NULL
pathways	NULL
.	NULL

Cell	NULL
84	NULL
:	NULL
299-308	NULL
.	NULL

Ishida	NULL
,	NULL
T.	NULL
,	NULL
S.-I	NULL
.	NULL

Mizushima	NULL
,	NULL
S.	NULL
Azuma	NULL
,	NULL
N.	NULL
Kobayashi	NULL
,	NULL
T.	NULL
Tojo	NULL
,	NULL
K.	NULL
Suzuki	NULL
,	NULL
S.	NULL
Aizawa	NULL
,	NULL
T.	NULL
Watanabe	NULL
,	NULL
G.	NULL
Mosialos	NULL
,	NULL
E.	NULL
Kieff	NULL
,	NULL
T.	NULL
Yamamoto	NULL
,	NULL
and	NULL
J.-L.	NULL
Inoue	NULL
.	NULL

19962	NULL
.	NULL

Identification	NULL
of	NULL
TRAF6	NULL
,	NULL
a	NULL
novel	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor-associated	NULL
factor	NULL
protein	NULL
that	NULL
mediates	NULL
signaling	NULL
from	NULL
an	NULL
amino-terminal	NULL
domain	NULL
of	NULL
the	NULL
CD40	NULL
cytoplasmic	NULL
region	NULL
.	NULL

J	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
:	NULL
28745-28748	NULL
.	NULL

Ishida	NULL
,	NULL
T.	NULL
,	NULL
T.	NULL
Tojo	NULL
,	NULL
T.	NULL
Aoki	NULL
,	NULL
N.	NULL
Kobayashi	NULL
,	NULL
T.	NULL
Ohishi	NULL
,	NULL
T.	NULL
Watanabe	NULL
,	NULL
T.	NULL
Yamamoto	NULL
,	NULL
and	NULL
J.-I	NULL
.	NULL

Inoue	NULL
.	NULL

1996b	NULL
.	NULL

TRAF5	NULL
,	NULL
a	NULL
novel	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor-associated	NULL
factor	NULL
family	NULL
protein	NULL
,	NULL
mediates	NULL
CD40	NULL
signaling	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

93	NULL
:	NULL
9437-9442	NULL
.	NULL

Kitson	NULL
,	NULL
J.	NULL
,	NULL
T.	NULL
Raven	NULL
,	NULL
Y.-P.	NULL
Jiang	NULL
,	NULL
D.V	NULL
.	NULL

Goeddel	NULL
,	NULL
K.M	NULL
.	NULL

Giles	NULL
,	NULL
K.-T.	NULL
Pun	NULL
,	NULL
C.J	NULL
.	NULL

Grinham	NULL
,	NULL
R.	NULL
Brown	NULL
,	NULL
and	NULL
S.N	NULL
.	NULL

Farrow	NULL
.	NULL

1996	NULL
.	NULL

A	NULL
death-domain	NULL
containing	NULL
receptor	NULL
that	NULL
mediates	NULL
apoptosis	NULL
.	NULL

Nature	NULL
3841	NULL
372-375	NULL
.	NULL

Klug	NULL
,	NULL
C.A	NULL
.	NULL

,	NULL
S.J	NULL
.	NULL

Gerety	NULL
,	NULL
P.C	NULL
.	NULL

Shah	NULL
,	NULL
Y.-Y	NULL
.	NULL

Chen	NULL
,	NULL
N.R	NULL
.	NULL

Rice	NULL
,	NULL
N.	NULL
Rosenberg	NULL
,	NULL
and	NULL
H.	NULL
Singh	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
v-abl	NULL
tyrosine	NULL
kinase	NULL
negatively	NULL
regulates	NULL
NF-B/Rel	NULL
factors	NULL
and	NULL
blocks	NULL
x	NULL
gene	NULL
transcription	NULL
in	NULL
pre-B	NULL
lymphocytes	NULL
.	NULL

Genes	NULL
&	NULL
Dev	NULL
.	NULL

8:1678-687	NULL
.	NULL

Komiyama	NULL
,	NULL
T.	NULL
,	NULL
C.A	NULL
.	NULL

Ray	NULL
,	NULL
D.J	NULL
.	NULL

Pickup	NULL
,	NULL
A.D.	NULL
Howard	NULL
,	NULL
N.A	NULL
.	NULL

Thornberry	NULL
,	NULL
E.P	NULL
.	NULL

Peterson	NULL
,	NULL
and	NULL
G.	NULL
Salvesen	NULL
.	NULL

1994	NULL
.	NULL

Inhibition	NULL
ofinterleukin-1	NULL
beta	NULL
converting	NULL
enzyme	NULL
by	NULL
the	NULL
cow	NULL
pox	NULL
virus	NULL
serpin	NULL
CrmA	NULL
.	NULL

An	NULL
example	NULL
of	NULL
cross-class	NULL
inhibition	NULL
.	NULL

J	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
:	NULL
19331-19337	NULL
.	NULL

Krappm	NULL
ann	NULL
,	NULL
D.	NULL
,	NULL
F.G.	NULL
Wulezyn	NULL
,	NULL
and	NULL
C.	NULL
Scheidereit	NULL
.	NULL

1996	NULL
.	NULL

Different	NULL
mechanisms	NULL
control	NULL
signal-induced	NULL
degradation	NULL
and	NULL
basal	NULL
turnover	NULL
of	NULL
the	NULL
NF-kB	NULL
inhibitor	NULL
IxBa	NULL
in	NULL
vivo	NULL
.	NULL

EMBO	NULL
J	NULL
15	NULL
:	NULL
6716-6726	NULL
.	NULL

Lee	NULL
,	NULL
S.Y	NULL
.	NULL

,	NULL
C.G	NULL
.	NULL

Park	NULL
,	NULL
and	NULL
Y.	NULL
Choi	NULL
.	NULL

1996	NULL
.	NULL

T	NULL
cell	NULL
receptor-depen-dent	NULL
cell	NULL
death	NULL
of	NULL
T	NULL
cell	NULL
hybridomas	NULL
mediated	NULL
by	NULL
the	NULL
CD30	NULL
cytoplasmic	NULL
domain	NULL
in	NULL
association	NULL
with	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor-associated	NULL
factors	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183	NULL
:	NULL
669-674	NULL
.	NULL

Lee	NULL
,	NULL
S.Y	NULL
.	NULL

,	NULL
S.Y	NULL
.	NULL

Lee	NULL
,	NULL
and	NULL
Y.	NULL
Choi	NULL
.	NULL

1997	NULL
.	NULL

TRAF-interacting	NULL
protein	NULL
(	NULL
TRIP	NULL
)	NULL
:	NULL
A	NULL
novel	NULL
component	NULL
of	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
(	NULL
TNFR	NULL
)	NULL
and	NULL
CD30-TRAF	NULL
signaling	NULL
complexes	NULL
that	NULL
inhibits	NULL
TRAFZ-mediated	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

185	NULL
:	NULL
1275-1285	NULL
.	NULL

Liston	NULL
,	NULL
P.	NULL
,	NULL
N.	NULL
Roy	NULL
,	NULL
K.	NULL
Tamai	NULL
,	NULL
C.	NULL
Lefebvre	NULL
,	NULL
S.	NULL
Baird	NULL
,	NULL
G.	NULL
Cherton-Horvat	NULL
,	NULL
R.	NULL
Farahani	NULL
,	NULL
M.	NULL
McLean	NULL
,	NULL
J.-E.	NULL
Ikeda	NULL
,	NULL
A.	NULL
MacKenzie	NULL
,	NULL
and	NULL
R.G	NULL
.	NULL

Korneluk	NULL
.	NULL

1996	NULL
.	NULL

Suppression	NULL
of	NULL
apoptosis	NULL
in	NULL
mammalian	NULL
cells	NULL
by	NULL
NAIP	NULL
and	NULL
a	NULL
related	NULL
family	NULL
of	NULL
IAP	NULL
genes	NULL
.	NULL

2820	NULL
GENES	NULL
&	NULL
DEVELOPMENT	NULL
Nature	NULL
3791	NULL
349-353	NULL
.	NULL

Liu	NULL
,	NULL
Z.G	NULL
.	NULL

,	NULL
H.	NULL
Hsu	NULL
,	NULL
D.V	NULL
.	NULL

Goeddel	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1996	NULL
.	NULL

Dissection	NULL
of	NULL
TNF	NULL
receptor	NULL
1	NULL
effector	NULL
functions	NULL
:	NULL
JNK	NULL
activation	NULL
is	NULL
not	NULL
linked	NULL
to	NULL
apoptosis	NULL
,	NULL
while	NULL
NF-kB	NULL
activation	NULL
prevents	NULL
cell	NULL
death	NULL
.	NULL

Cell	NULL
87	NULL
:	NULL
565-576	NULL
.	NULL

Maggi	NULL
,	NULL
E.	NULL
,	NULL
F.	NULL
Annunziato	NULL
,	NULL
R.	NULL
Manetti	NULL
,	NULL
R.	NULL
Biagiotti	NULL
,	NULL
M.G	NULL
.	NULL

Giudizi	NULL
,	NULL
A.	NULL
Ravina	NULL
,	NULL
F.	NULL
Almerigogna	NULL
,	NULL
N.	NULL
Boiani	NULL
,	NULL
M.	NULL
Alderson	NULL
,	NULL
and	NULL
S.	NULL
Romagnani	NULL
.	NULL

1995	NULL
.	NULL

Activation	NULL
of	NULL
HIV	NULL
expression	NULL
by	NULL
CD30	NULL
triggering	NULL
in	NULL
CD4*	NULL
cells	NULL
from	NULL
HIV-infected	NULL
individuals	NULL
.	NULL

Immunity	NULL
3	NULL
:	NULL
251-255	NULL
.	NULL

Malinin	NULL
,	NULL
N.L	NULL
.	NULL

,	NULL
M.P	NULL
.	NULL

Boldin	NULL
,	NULL
A.	NULL
Kovalenko	NULL
,	NULL
and	NULL
D.	NULL
Wallach	NULL
.	NULL

1997	NULL
.	NULL

MAP3K-related	NULL
kinase	NULL
involved	NULL
in	NULL
NF-kB	NULL
induction	NULL
by	NULL
TNF	NULL
,	NULL
CD95	NULL
and	NULL
IL-1	NULL
.	NULL

Nature	NULL
385	NULL
:	NULL
540-544	NULL
.	NULL

Marsters	NULL
,	NULL
S.A.	NULL
,	NULL
J.P.	NULL
Sheridan	NULL
,	NULL
C.J	NULL
.	NULL

Donahue	NULL
,	NULL
R.M	NULL
.	NULL

Pitti	NULL
,	NULL
C.L	NULL
.	NULL

Gray	NULL
,	NULL
A.D.	NULL
Goddard	NULL
,	NULL
K.D	NULL
.	NULL

Bauer	NULL
,	NULL
and	NULL
A.	NULL
Ashkenazi	NULL
.	NULL

1996	NULL
.	NULL

Apo-3	NULL
,	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
family	NULL
,	NULL
contains	NULL
a	NULL
death	NULL
domain	NULL
and	NULL
activates	NULL
apoptosis	NULL
and	NULL
NF-kB	NULL
.	NULL

Curr	NULL
.	NULL

Biol	NULL
.	NULL

6	NULL
:	NULL
1669-1676	NULL
.	NULL

Nadali	NULL
,	NULL
G.	NULL
,	NULL
F.	NULL
Vinante	NULL
,	NULL
H.	NULL
Stein	NULL
,	NULL
G.	NULL
Todeschini	NULL
,	NULL
C.	NULL
Tecchio	NULL
,	NULL
L.	NULL
Morosato	NULL
,	NULL
M.	NULL
Chilosi	NULL
,	NULL
F.	NULL
Menestrina	NULL
,	NULL
M.C	NULL
.	NULL

Kinney	NULL
,	NULL
J.P.	NULL
Greer	NULL
,	NULL
U.	NULL
Latza	NULL
,	NULL
G.	NULL
Perona	NULL
,	NULL
and	NULL
G.	NULL
Pizzolo	NULL
.	NULL

1995	NULL
.	NULL

Serum	NULL
levels	NULL
of	NULL
the	NULL
soluble	NULL
form	NULL
of	NULL
CD30	NULL
molecule	NULL
as	NULL
a	NULL
tumor	NULL
marker	NULL
in	NULL
CD30®	NULL
anaplastic	NULL
large-cell	NULL
lymphoma	NULL
.	NULL

J	NULL
Clin	NULL
.	NULL

Oncol	NULL
.	NULL

13	NULL
:	NULL
1355-1360	NULL
.	NULL

Nagata	NULL
,	NULL
S.	NULL
1996	NULL
.	NULL

Apoptosis	NULL
:	NULL
Telling	NULL
cells	NULL
their	NULL
time	NULL
is	NULL
up	NULL
.	NULL

Curr	NULL
.	NULL

Biol	NULL
.	NULL

61	NULL
1241-1243	NULL
.	NULL

Nakano	NULL
,	NULL
H.	NULL
,	NULL
H.	NULL
Oshima	NULL
,	NULL
W.	NULL
Chung	NULL
,	NULL
L.	NULL
William	NULL
C.F	NULL
.	NULL

Ware	NULL
,	NULL
H.	NULL
Yagita	NULL
,	NULL
and	NULL
K.	NULL
Okumura	NULL
.	NULL

1996	NULL
.	NULL

TRAF5	NULL
,	NULL
an	NULL
activator	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
putative	NULL
signal	NULL
transducer	NULL
for	NULL
the	NULL
lympho-toxin-B	NULL
receptor	NULL
.	NULL

X	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
:	NULL
14661-14664	NULL
.	NULL

Natoli	NULL
,	NULL
G.	NULL
,	NULL
A.	NULL
Costanzo	NULL
,	NULL
A.	NULL
Ianni	NULL
,	NULL
D.J	NULL
.	NULL

Templeton	NULL
,	NULL
JR.	NULL
Woodgett	NULL
,	NULL
C.	NULL
Balsano	NULL
,	NULL
and	NULL
M.	NULL
Levrero	NULL
.	NULL

1997	NULL
.	NULL

Activation	NULL
of	NULL
SAPK/JINK	NULL
by	NULL
TNF	NULL
receptor	NULL
1	NULL
through	NULL
a	NULL
noncytotoxic	NULL
TRAF2Z-dependent	NULL
pathway	NULL
.	NULL

Science	NULL
275	NULL
:	NULL
200-203	NULL
.	NULL

Oltvai	NULL
,	NULL
Z.N	NULL
.	NULL

and	NULL
S.J	NULL
.	NULL

Korsmeyer	NULL
.	NULL

1994	NULL
.	NULL

Checkpoints	NULL
of	NULL
dueling	NULL
dimers	NULL
foil	NULL
death	NULL
wishes	NULL
.	NULL

Cell	NULL
79	NULL
:	NULL
189-192	NULL
.	NULL

Palombella	NULL
,	NULL
V.J	NULL
.	NULL

,	NULL
O.J	NULL
.	NULL

Rando	NULL
,	NULL
A.L	NULL
.	NULL

Goldberg	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
ubiquitin-proteasome	NULL
pathway	NULL
is	NULL
required	NULL
for	NULL
processing	NULL
the	NULL
NF-kB1	NULL
precursor	NULL
protein	NULL
and	NULL
the	NULL
activation	NULL
of	NULL
NF-kB	NULL
.	NULL

Cell	NULL
78	NULL
:	NULL
773-785	NULL
.	NULL

Pan	NULL
,	NULL
G.	NULL
,	NULL
K.	NULL
O'Rourke	NULL
,	NULL
A.M.	NULL
Chinnaiyan	NULL
,	NULL
R.	NULL
Gentz	NULL
,	NULL
R.	NULL
Ebner	NULL
,	NULL
J.	NULL
Ni	NULL
,	NULL
and	NULL
V.M	NULL
.	NULL

Dixit	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
receptor	NULL
for	NULL
the	NULL
cytotoxic	NULL
ligand	NULL
TRAIL	NULL
.	NULL

Science	NULL
276	NULL
:	NULL
111-113	NULL
.	NULL

Rathmell	NULL
,	NULL
J.C.	NULL
,	NULL
S.E	NULL
.	NULL

Townsend	NULL
,	NULL
J.C.	NULL
Xu	NULL
,	NULL
R.A.	NULL
Flavell	NULL
,	NULL
and	NULL
C.C	NULL
.	NULL

Goodnow	NULL
.	NULL

1996	NULL
.	NULL

Expansion	NULL
or	NULL
elimination	NULL
of	NULL
B	NULL
cells	NULL
in	NULL
vivo	NULL
:	NULL
Dual	NULL
roles	NULL
for	NULL
CD40-	NULL
and	NULL
Fas	NULL
(	NULL
CD95	NULL
)	NULL
}	NULL
-ligands	NULL
modulated	NULL
by	NULL
the	NULL
B	NULL
cell	NULL
antigen	NULL
receptor	NULL
.	NULL

Cell	NULL
87	NULL
:	NULL
319-329	NULL
.	NULL

Rothe	NULL
,	NULL
M.	NULL
,	NULL
S.C.	NULL
Wong	NULL
,	NULL
W.J	NULL
.	NULL

Henzel	NULL
,	NULL
and	NULL
D.V	NULL
.	NULL

Goeddel	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
novel	NULL
family	NULL
of	NULL
putative	NULL
signal	NULL
transducers	NULL
associated	NULL
with	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
the	NULL
75	NULL
kDa	NULL
tum	NULL
or	NULL
necrosis	NULL
factor	NULL
receptor	NULL
.	NULL

Cell	NULL
781	NULL
681-692	NULL
.	NULL

Rothe	NULL
,	NULL
M.	NULL
,	NULL
M.-G.	NULL
Pan	NULL
,	NULL
W.J	NULL
.	NULL

Henzel	NULL
,	NULL
T.M	NULL
.	NULL

Ayres	NULL
,	NULL
and	NULL
D.V	NULL
.	NULL

Goeddel	NULL
.	NULL

1995a	NULL
.	NULL

The	NULL
TNFR2-TRAF	NULL
signaling	NULL
complex	NULL
contains	NULL
two	NULL
novel	NULL
proteins	NULL
related	NULL
to	NULL
baculoviral	NULL
inhibitor	NULL
of	NULL
apoptosis	NULL
proteins	NULL
.	NULL

Cell	NULL
83	NULL
:	NULL
1243-1252	NULL
.	NULL

Rothe	NULL
,	NULL
M.	NULL
,	NULL
V.	NULL
Sarma	NULL
,	NULL
V.M	NULL
.	NULL

Dixit	NULL
,	NULL
and	NULL
D.V	NULL
.	NULL

Goeddel	NULL
.	NULL

19956	NULL
.	NULL

TRAF2Z-mediated	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
TNF	NULL
receptor	NULL
2	NULL
and	NULL
CD40	NULL
.	NULL

Science	NULL
2691	NULL
1424-1427	NULL
.	NULL

Rothe	NULL
,	NULL
M.	NULL
,	NULL
J.	NULL
Xiong	NULL
,	NULL
H.-B	NULL
.	NULL

Shu	NULL
,	NULL
K.	NULL
Williamson	NULL
,	NULL
A.	NULL
Goddard	NULL
,	NULL
and	NULL
D.V	NULL
.	NULL

Goeddel	NULL
.	NULL

1996	NULL
.	NULL

I-TRAF	NULL
is	NULL
a	NULL
novel	NULL
TRAF-interacting	NULL
protein	NULL
that	NULL
regulates	NULL
TRAF-mediated	NULL
signal	NULL
transduction	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

931	NULL
8241-8246	NULL
.	NULL

Schwab	NULL
,	NULL
U.	NULL
,	NULL
H.	NULL
Stein	NULL
,	NULL
J.	NULL
Gerdes	NULL
,	NULL
H.	NULL
Lemke	NULL
,	NULL
H.	NULL
Kirchner	NULL
,	NULL
M.	NULL
Schaadt	NULL
,	NULL
and	NULL
V.	NULL
Diehl	NULL
.	NULL

1982	NULL
.	NULL

Production	NULL
of	NULL
a	NULL
monoclonal	NULL
antibody	NULL
specific	NULL
for	NULL
Hodgkin	NULL
and	NULL
Sternberg-Reed	NULL
cells	NULL
of	NULL
Hodgkin	NULL
's	NULL
disease	NULL
and	NULL
a	NULL
subset	NULL
of	NULL
normal	NULL
lymhoid	NULL
cells	NULL
.	NULL

Ne	NULL
ture	NULL
2991	NULL
65-67	NULL
.	NULL

Sicbenlist	NULL
,	NULL
U.	NULL
,	NULL
G.	NULL
Franzoso	NULL
,	NULL
and	NULL
K.	NULL
Brown	NULL
.	NULL

1994	NULL
.	NULL

Structure	NULL
,	NULL
regulation	NULL
and	NULL
function	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

10	NULL
:	NULL
405-455	NULL
.	NULL

Smith	NULL
,	NULL
C.A	NULL
.	NULL

,	NULL
H.J	NULL
.	NULL

Gruss	NULL
,	NULL
T.	NULL
Davis	NULL
,	NULL
D.	NULL
Anderson	NULL
,	NULL
T.	NULL
Farrah	NULL
,	NULL
E.	NULL
Baker	NULL
,	NULL
G.R	NULL
.	NULL

Sutherland	NULL
,	NULL
C.I	NULL
Brannan	NULL
,	NULL
N.G	NULL
.	NULL

Copeland	NULL
,	NULL
N.A	NULL
.	NULL

Jenkins	NULL
,	NULL
K.H	NULL
.	NULL

Grabstein	NULL
,	NULL
B.	NULL
Gliniak	NULL
,	NULL
LB	NULL
.	NULL

McAlister	NULL
,	NULL
W.	NULL
Fans-low	NULL
,	NULL
M.	NULL
Alderson	NULL
,	NULL
B.	NULL
Falk	NULL
,	NULL
S.	NULL
Gimpel	NULL
,	NULL
S.	NULL
Gillis	NULL
,	NULL
W.S	NULL
.	NULL

Din	NULL
,	NULL
R.G	NULL
.	NULL

Goodwin	NULL
,	NULL
and	NULL
R.J.	NULL
Armitage	NULL
.	NULL

1993	NULL
.	NULL

CD30	NULL
antigen	NULL
,	NULL
a	NULL
marker	NULL
for	NULL
Hodgkin	NULL
's	NULL
lymphoma	NULL
,	NULL
is	NULL
a	NULL
receptor	NULL
whose	NULL
ligand	NULL
defines	NULL
an	NULL
emerging	NULL
family	NULL
of	NULL
cytokines	NULL
with	NULL
homology	NULL
to	NULL
TNF	NULL
.	NULL

Cell	NULL
73	NULL
:	NULL
1349-1360	NULL
.	NULL

Song	NULL
,	NULL
H.	NULL
Y.	NULL
,	NULL
M.	NULL
Rothe	NULL
,	NULL
and	NULL
D.V	NULL
.	NULL

Goeddel	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
tumor	NULL
necrosis	NULL
factor-inducible	NULL
zinc	NULL
finger	NULL
protein	NULL
A20	NULL
interacts	NULL
with	NULL
TRAFI/TRAF2	NULL
and	NULL
inhibits	NULL
NF-kB	NULL
activation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

9316721-6725	NULL
.	NULL

Speiser	NULL
,	NULL
D.E	NULL
.	NULL

,	NULL
S.Y	NULL
.	NULL

Lee	NULL
,	NULL
B.	NULL
Wong	NULL
,	NULL
J.	NULL
Arron	NULL
,	NULL
A.	NULL
Santana	NULL
,	NULL
Y.-Y	NULL
.	NULL

Kong	NULL
,	NULL
P.S	NULL
.	NULL

Ohashi	NULL
,	NULL
and	NULL
Y.	NULL
Choi	NULL
.	NULL

1997	NULL
.	NULL

A	NULL
regulatory	NULL
role	NULL
for	NULL
TRAF	NULL
!	NULL

in	NULL
antigen-induced	NULL
apoptosis	NULL
of	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

185	NULL
:	NULL
1777-1783	NULL
.	NULL

Squier	NULL
,	NULL
M.K	NULL
.	NULL

and	NULL
J.J.	NULL
Cohen	NULL
.	NULL

1997	NULL
.	NULL

Calpain	NULL
,	NULL
an	NULL
upstream	NULL
regulator	NULL
of	NULL
thymocyte	NULL
apoptosis	NULL
.	NULL

X	NULL
Immunol	NULL
.	NULL

158	NULL
:	NULL
3690-3697	NULL
.	NULL

Stanger	NULL
,	NULL
B.Z	NULL
.	NULL

,	NULL
P.	NULL
Leder	NULL
,	NULL
T.H	NULL
.	NULL

Lee	NULL
,	NULL
E.	NULL
Kim	NULL
,	NULL
and	NULL
B	NULL
.	NULL

Seed	NULL
.	NULL

1995	NULL
.	NULL

RIP	NULL
:	NULL
A	NULL
novel	NULL
protein	NULL
containing	NULL
a	NULL
death	NULL
domain	NULL
that	NULL
interacts	NULL
with	NULL
Fas/APO-1	NULL
(	NULL
CD95	NULL
)	NULL
in	NULL
yeast	NULL
and	NULL
causes	NULL
cell	NULL
death	NULL
.	NULL

Cell	NULL
81	NULL
:	NULL
513-523	NULL
.	NULL

Stein	NULL
,	NULL
H.	NULL
,	NULL
J.	NULL
Gerdes	NULL
,	NULL
H.	NULL
Lemke	NULL
,	NULL
and	NULL
D.Y	NULL
.	NULL

Mason	NULL
.	NULL

19852	NULL
.	NULL

Evidence	NULL
of	NULL
Sternberg-Reed	NULL
cells	NULL
being	NULL
derived	NULL
from	NULL
activated	NULL
lymphocytes	NULL
.	NULL

In	NULL
Modern	NULL
trends	NULL
in	NULL
hum	NULL
an	NULL
leukemia	NULL
VI	NULL
(	NULL
ed	NULL
.	NULL

R.C	NULL
.	NULL

Gallo	NULL
,	NULL
R.	NULL
Neth	NULL
,	NULL
M.F	NULL
.	NULL

Greaves	NULL
,	NULL
and	NULL
G.	NULL
Janka	NULL
)	NULL
,	NULL
pp	NULL
.	NULL

441-444	NULL
.	NULL

Springer-Verlag	NULL
,	NULL
Heidelberg	NULL
,	NULL
Germany	NULL
.	NULL

Stein	NULL
,	NULL
H.	NULL
,	NULL
D.Y	NULL
.	NULL

Mason	NULL
,	NULL
J.	NULL
Gerdes	NULL
,	NULL
N.	NULL
O'Connor	NULL
,	NULL
J.	NULL
Wainscoat	NULL
,	NULL
G.	NULL
Pallesen	NULL
,	NULL
K.	NULL
Gatter	NULL
,	NULL
B.	NULL
Falini	NULL
,	NULL
G.	NULL
Delsol	NULL
,	NULL
H.	NULL
Lemke	NULL
,	NULL
R.	NULL
Schwarting	NULL
,	NULL
and	NULL
K.	NULL
Lennert	NULL
.	NULL

1985b	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
the	NULL
Hodgkin	NULL
's	NULL
disease	NULL
associated	NULL
antigen	NULL
Ki-1	NULL
in	NULL
reactive	NULL
and	NULL
neoplastic	NULL
lymphoid	NULL
tissue	NULL
:	NULL
Evidence	NULL
that	NULL
Reed-Sternberg	NULL
cells	NULL
and	NULL
histiocytic	NULL
malignancies	NULL
are	NULL
derived	NULL
from	NULL
activated	NULL
lymphoid	NULL
cells	NULL
.	NULL

Blood	NULL
66	NULL
:	NULL
848-858	NULL
.	NULL

Takahashi	NULL
,	NULL
T.	NULL
,	NULL
M.	NULL
Tanaka	NULL
,	NULL
C.I	NULL
.	NULL

Brannan	NULL
,	NULL
N.A	NULL
.	NULL

Jenkins	NULL
,	NULL
N.G	NULL
.	NULL

Copeland	NULL
,	NULL
T.	NULL
Suda	NULL
,	NULL
and	NULL
S.	NULL
Nagata	NULL
.	NULL

1994	NULL
.	NULL

Generalized	NULL
lym-phoproliferative	NULL
disease	NULL
in	NULL
mice	NULL
caused	NULL
by	NULL
a	NULL
point	NULL
mutation	NULL
in	NULL
Fas	NULL
ligand	NULL
.	NULL

Cell	NULL
76:969-976	NULL
.	NULL

Tartaglia	NULL
,	NULL
L.A.	NULL
,	NULL
TM	NULL
.	NULL

Ayres	NULL
,	NULL
G.H	NULL
.	NULL

Wong	NULL
,	NULL
and	NULL
D.V	NULL
.	NULL

Goeddel	NULL
.	NULL

1993	NULL
.	NULL

A	NULL
novel	NULL
domain	NULL
within	NULL
the	NULL
55	NULL
kd	NULL
TNF	NULL
receptor	NULL
signals	NULL
cell	NULL
death	NULL
.	NULL

Cell	NULL
741	NULL
845-853	NULL
.	NULL

Tartaglia	NULL
,	NULL
L.A.	NULL
,	NULL
D.V	NULL
.	NULL

Goeddel	NULL
,	NULL
C.	NULL
Reynolds	NULL
,	NULL
LS	NULL
.	NULL

Figari	NULL
,	NULL
R.F	NULL
.	NULL

We-ber	NULL
,	NULL
B.M	NULL
.	NULL

Fendly	NULL
,	NULL
and	NULL
M.A	NULL
.	NULL

Palladino	NULL
,	NULL
Jr.	NULL
1993	NULL
.	NULL

Stimulation	NULL
of	NULL
human	NULL
T-cell	NULL
proliferation	NULL
by	NULL
specific	NULL
activation	NULL
of	NULL
the	NULL
75-kDa	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

151	NULL
:	NULL
4637-4641	NULL
.	NULL

Tartaglia	NULL
,	NULL
LA	NULL
.	NULL

,	NULL
D.	NULL
Pennica	NULL
,	NULL
and	NULL
D.V	NULL
.	NULL

Goeddel	NULL
.	NULL

1993	NULL
.	NULL

Ligand	NULL
passing	NULL
:	NULL
The	NULL
75-kDa	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
receptor	NULL
recruits	NULL
TNF	NULL
for	NULL
signaling	NULL
by	NULL
the	NULL
55-kDa	NULL
TNF	NULL
receptor	NULL
.	NULL

Z	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

2681	NULL
:	NULL
18542-18548	NULL
.	NULL

Tomasetto	NULL
,	NULL
C.	NULL
,	NULL
C.H	NULL
.	NULL

Régnier	NULL
,	NULL
C.	NULL
Moog-Lutz	NULL
,	NULL
M.G	NULL
.	NULL

Mattei	NULL
,	NULL
M.P	NULL
.	NULL

Chenard	NULL
,	NULL
R.	NULL
Lidereau	NULL
,	NULL
P.	NULL
Basset	NULL
,	NULL
and	NULL
M.C	NULL
.	NULL

Rio	NULL
.	NULL

1995	NULL
.	NULL

Identification	NULL
of	NULL
four	NULL
novel	NULL
human	NULL
genes	NULL
amplified	NULL
and	NULL
overex-pressed	NULL
in	NULL
breast	NULL
carcinoma	NULL
and	NULL
localized	NULL
to	NULL
the	NULL
q11-q21.3	NULL
region	NULL
of	NULL
chromosome	NULL
17	NULL
.	NULL

Genomics	NULL
28	NULL
:	NULL
367-376	NULL
.	NULL

Tsitsikov	NULL
,	NULL
E.	NULL
,	NULL
D.A	NULL
.	NULL

Wright	NULL
,	NULL
and	NULL
R.S	NULL
.	NULL

Geha	NULL
.	NULL

1997	NULL
.	NULL

CD30	NULL
induction	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
gene	NULL
transcription	NULL
is	NULL
mediated	NULL
by	NULL
TRAF2	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

941	NULL
1390-1395	NULL
.	NULL

Uren	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Pakusch	NULL
,	NULL
C.	NULL
Hawkins	NULL
,	NULL
K.L	NULL
.	NULL

Puls	NULL
,	NULL
and	NULL
D.L	NULL
.	NULL

Vaux	NULL
.	NULL

1996	NULL
.	NULL

Cloning	NULL
and	NULL
expression	NULL
of	NULL
apoptosis	NULL
inhibitory	NULL
proteins	NULL
homologs	NULL
that	NULL
function	NULL
to	NULL
inhibit	NULL
apoptosis	NULL
and/or	NULL
bind	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor-associated	NULL
factors	NULL
.	NULL

Proc	NULL
.	NULL

Degradation	NULL
of	NULL
TRAF2	NULL
by	NULL
CD30	NULL
Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

931	NULL
4974-4978	NULL
.	NULL

Van	NULL
Antwerp	NULL
,	NULL
D.J	NULL
.	NULL

,	NULL
S.J	NULL
.	NULL

Martin	NULL
,	NULL
T.	NULL
Kafri	NULL
,	NULL
D.	NULL
Green	NULL
,	NULL
and	NULL
LM	NULL
.	NULL

Verma	NULL
.	NULL

1996	NULL
.	NULL

Suppression	NULL
of	NULL
TNF-	NULL
«	NULL
-induced	NULL
apoptosis	NULL
by	NULL
Science	NULL
2741	NULL
787-789	NULL
.	NULL

Vassalli	NULL
,	NULL
P.	NULL
1992	NULL
.	NULL

The	NULL
pathophysiology	NULL
of	NULL
tumor	NULL
necrosis	NULL
factors	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

10	NULL
:	NULL
411-452	NULL
.	NULL

Wang	NULL
,	NULL
C.-Y	NULL
.	NULL

,	NULL
M.W	NULL
.	NULL

Mayo	NULL
,	NULL
and	NULL
A.S.J	NULL
.	NULL

Baldwin	NULL
.	NULL

1996	NULL
.	NULL

TNF-	NULL
and	NULL
cancer	NULL
therapy-induced	NULL
apoptosis	NULL
:	NULL
Potentiation	NULL
by	NULL
inhibition	NULL
of	NULL
NF-kB	NULL
.	NULL

Science	NULL
2741784-787	NULL
.	NULL

Weiss	NULL
,	NULL
A.	NULL
and	NULL
D.R	NULL
.	NULL

Littman	NULL
.	NULL

1994	NULL
.	NULL

Signal	NULL
transduction	NULL
by	NULL
lymphocyte	NULL
antigen	NULL
receptors	NULL
.	NULL

Cell	NULL
76	NULL
:	NULL
263-274	NULL
.	NULL

Weiss	NULL
,	NULL
T.	NULL
,	NULL
M.	NULL
Grell	NULL
,	NULL
B.	NULL
Hessabi	NULL
,	NULL
S.	NULL
Bourteele	NULL
,	NULL
G.	NULL
Miiller	NULL
,	NULL
P.	NULL
Scheurich	NULL
,	NULL
and	NULL
H.	NULL
Wajant	NULL
.	NULL

1997	NULL
.	NULL

Enhancement	NULL
of	NULL
TNF	NULL
receptor	NULL
p6O-mediated	NULL
cytotoxicity	NULL
by	NULL
TNF	NULL
receptor	NULL
p80	NULL
.	NULL

J	NULL
Im	NULL
m	NULL
unol	NULL
.	NULL

1581	NULL
2398-2404	NULL
.	NULL

Xu	NULL
,	NULL
Y.	NULL
,	NULL
G.	NULL
Cheng	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1996	NULL
.	NULL

Targeted	NULL
disruption	NULL
of	NULL
TRAF3	NULL
leads	NULL
to	NULL
postnatal	NULL
lethality	NULL
and	NULL
defective	NULL
T-depen-dent	NULL
immune	NULL
responses	NULL
.	NULL

Immunity	NULL
5:407-415	NULL
.	NULL

Yang	NULL
,	NULL
H.	NULL
,	NULL
C.S	NULL
.	NULL

Duckett	NULL
,	NULL
and	NULL
T.	NULL
Lindsten	NULL
.	NULL

1995.	NULL
iPABP	NULL
,	NULL
an	NULL
inducible	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
-binding	NULL
protein	NULL
detected	NULL
in	NULL
activated	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

1516770-6776	NULL
.	NULL

Zheng	NULL
,	NULL
L.	NULL
,	NULL
G.	NULL
Fisher	NULL
,	NULL
R.E	NULL
.	NULL

Miller	NULL
,	NULL
J.	NULL
Peschon	NULL
,	NULL
D.H.	NULL
Lynch	NULL
,	NULL
and	NULL
M.J.	NULL
Lenardo	NULL
.	NULL

1995	NULL
.	NULL

Induction	NULL
of	NULL
apoptosis	NULL
in	NULL
mature	NULL
T	NULL
cells	NULL
by	NULL
tumour	NULL
necrosis	NULL
factor	NULL
.	NULL

Nature	NULL
377	NULL
:	NULL
348-351	NULL
.	NULL

GENES	NULL
&	NULL
DEVELOPMENT	NULL
2821	NULL

